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 I. INTRODUCTION  
I.1. Background of the proposed work 
 Diabetes mellitus (DM) has a substantial burden on healthcare services and it 
reached epidemic proportions worldwide. Prevalence of diabetes is increasing 
globally, particularly in developing countries.
1
 Virtually DM is either due to insulin 
deficiency (decreased level of insulin) or insulin resistance (decreased response of 
tissues to insulin action). DM was treated traditionally with herbal remedies (plants), 
diet and physical exercise. Thousands of plants were used to control DM, though one 
third only investigated for phytochemicals and its pharmacological activities.
2
 
I.2. Diabetes Mellitus 
  Diabetes mellitus is a group of disorders characterized by decreased in the 
carbohydrate metabolism, whereas lipid and protein metabolism will be increased, 
which leads hyperglycemia (increased blood glucose level). DM refers to a syndrome 
of hyperglycemia resulting from many different causes.
3
 DM is majorly classified into 
Type 1 diabetes mellitus: (insulin dependent diabetes mellitus; IDDM - complete 
insulin deficiency due to β- cell   necrosis), Type 2 diabetes mellitus: (non-insulin 
dependent diabetes mellitus; NIDDM - mainly due to insulin deficiency and/or insulin 
resistance) and gestational diabetes mellitus (GDM – due to pregnancy and delivery). 
According to the American Diabetes Association (ADA), DM is defined as 
4
  
 Fasting plasma glucose (FPG) ≥126 mg/dL, this should be confirmed with 
repeat testing on a different day.   
 Hyperglycemic symptoms (polyuria, polydipsia, and unexplained weight loss) 
and a random plasma glucose ≥200 mg/dL.   
 Plasma glucose ≥200 mg/dl 2 h after a 75 g (100 g for pregnant women) 
glucose load in an oral glucose tolerance test (OGTT).  
 A hemoglobin A1c (HbA1c) value ≥6.5%.  
Introduction 
2 
 
I.2.a. Pre-diabetes 
5,6
  
Pre-diabetes is defined as, any individuals having higher glucose level than the 
normal values, but not high enough to meet the diagnosis criteria for DM.  
 Fasting plasma glucose 100 to 125 mg/dL; this is referred to as impaired 
fasting glucose.  
 After OGTT, two-hour plasma glucose (140 to 199 mg/dL) - referred as 
impaired glucose tolerance.  
 A hemoglobin A1c (HbA1C) value between 5.7% and 6.4%.  
Table 1: Comparison between type 1 DM and type 2 DM 
7-9
 
 Type 1 DM Type 2 DM 
Previous terminology Insulin-dependent diabetes mellitus 
(IDDM), type I, 
juvenile-onset diabetes 
Non–insulin-dependent diabetes 
mellitus, type II, adult-onset 
diabetes 
Age of onset Usually <30 yr, particularly 
childhood and adolescence, 
but any age 
Usually >40 yr, but any age 
Genetic 
predisposition 
Moderate; environmental factors 
required for expression; 
35%-50% concordance in 
monozygotic twins; several 
candidate genes proposed 
Strong; 60-90% concordance in 
monozygotic twins; many 
candidate genes proposed; some genes 
identified in maturity onset 
diabetes of the young 
Human leukocyte 
antigen 
associations 
Linkage to DQA and DQB, 
influenced by DRB (3 and 4) 
(DR2 protective) 
None known 
Precipitating and risk 
factors 
Largely unknown; microbial, 
chemical, dietary, other 
Age, obesity (central), sedentary 
lifestyle, previous gestational diabetes 
Other associations Autoimmune; Graves’ disease, 
Hashimoto’s thyroiditis, 
vitiligo, Addison’s disease, 
pernicious anemia 
Heterogenous group, ongoing 
subclassification based on 
identification 
of specific pathogenic processes and 
genetic defects 
Findings at diagnosis 85%-90% of patients have one and 
usually more autoantibodies 
to ICA512/IA-2/IA-2b, GAD65, 
insulin (IAA) 
Possibly complications (microvascular 
and macrovascular) caused 
by significant preceding asymptomatic 
period 
Endogenous insulin 
levels 
Low or absent Usually present (relative deficiency), 
early hyperinsulinemia 
Insulin resistance Only with hyperglycemia Mostly present 
Prolonged fast Hyperglycemia, ketoacidosis Euglycemia 
Stress, withdrawal of 
insulin 
Ketoacidosis Nonketotic hyperglycemia, 
occasionally ketoacidosis 
GAD - Glutamic acid decarboxylase; IA-2/IA-2b - tyrosine phosphatases; IAA - insulin autoantibodies; 
ICA - islet cell antibody; ICA512 - islet cell autoantigen 512 (fragment of IA-2).  
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I.2.b. Causes / Etiology of DM 
Primary causes of DM are hereditary factors and environmental factors. 
Idiopathic type 1 DM results from autoimmune beta-cell destruction and cause an 
absolute insulin deficiency. Hereditary which can cause DM include, islet cell 
antibodies (found in 90% of patients within the first year of diagnosis), higher 
incidence of human leukocyte antigen (HLA), 50% concordance rate in identical 
twins. Environmental factors such as viral infection (Coxsackie virus, mumps virus), 
obesity, high carbohydrate content in food and sedentary lifestyle can cause DM.  
I.2.c. DM secondary to other factors  
Apart from the primary causes many other factors can cause DM, which 
include excess hormonal action (acromegaly, cushing’s syndrome, glucagonoma, 
pheochromocytoma), drugs (glucocorticoids, diuretics, oral contraceptives), insulin 
receptor unavailability, pancreatic disease (pancreatitis, pancreatectomy, 
hemochromatosis, cystic fibrosis), genetic syndromes (familial hyperlipidemia, 
lipoatrophy, maturity onset diabetes of the young, myotonic dystrophy) and 
gestational diabetes (GDM).  
Table 2: Diagnostic categories*: Diabetes Mellitus and At-Risk States 
8-10
 
Fasting Plasma Glucose Level 
2-Hour (75 g) OGTT Result 
<140 mg/dl 140-199 mg/dl ≥200 mg/dl 
<100 mg/dl Normal IGT
†
 DM 
100-125 mg/dl IFG
†
 IGT
† 
and IFG
†
 DM 
≥126 mg/dl DM DM DM 
HbA 1C Level <5.7% 5.7-6.4% ≥6.5% 
 Normal High-risk
†
 DM 
DM - Diabetes mellitus; IFG - impaired fasting glucose; IGT - impaired glucose 
tolerance. * These categories are based on the combined fasting glucose level and a    
2-hour (75 g) oral glucose tolerance test (OGTT) results. †May be referred to as pre-
diabetes.  
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Figure 1: Pathophysiology of diabetes 
7
 
 
 
 
Effects of insulin deficiency on body fuel metabolism. Lack of insulin leads to 
mobilization of substrates for gluconeogenesis and ketogenesis from muscle and 
adipose tissue, accelerated production of glucose and ketones by the liver, and 
impaired removal of endogenous and exogenous fuels by insulin-responsive tissues. 
The net results are severe hyperglycemia and hyperketonemia that overwhelm renal 
removal mechanisms. FFA - free fatty acids.  
 
I.2.d. Treatment for DM 
Treatment for DM includes pharmacological therapy (insulin & oral 
hypoglycaemic agents) and non-pharmacological therapy (diet & exercise). Type 1 
DM requires immediate insulin therapy. For Type 2 DM, American Diabetes 
Association and European association on diabetes studies recommends diet, exercise 
and drug (metformin) unless contraindicated. 
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Table 3: Pharmacologic classes of anti-diabetic (antihyperglycemic) drugs 
9
 
Class Drugs 
Major 
Action 
Effect 
Doses 
/ Day 
Hypogly
cemia 
CVD Risk 
Factor 
Benefits 
Lifestyle — Broad Both — No Yes 
Biguanide Metformin 
Liver 
sensitizer 
Fasting 1-2 No Modest 
Sulfonylurea 
Glimepiride 
Glipizide 
Insulin 
secretagogue 
Fasting 1-2 Yes Negligible 
Meglitinide Repaglinide 
Insulin 
secretagogue 
Both 
With 
meals 
Yes Negligible 
Benzoic acid–
derived 
Nateglinide 
Insulin 
secretagogue 
Prandial 
With 
meals 
Minimal Negligible 
Basal insulin 
NPH 
Glargine 
Detemir 
Insulin 
supplement/ 
substitute 
Fasting 1 Yes++ Lowers TG 
Bolus insulin 
R, lispro 
Aspart 
Glulisine 
Insulin 
supplement/ 
substitute 
Prandial 
With 
meals 
Yes++ Lowers TG 
Thiazolidinedione 
Pioglitazone, 
rosiglitazone 
Peripheral 
sensitizer 
Fasting 1 No 
Variable 
(see text) 
α-Glucosidase 
inhibitors 
Acarbose 
Miglitol 
Slow 
carbohydrate 
absorption 
Prandial 
With 
meals 
No Negligible 
Amylinomimetics Pramlintide Broad Prandial 
With 
meals 
No Negligible 
GLP1 receptor 
agonists 
Exenatide Broad Prandial 2 No 
Modest 
with weight 
loss 
Long-acting 
GLP1 receptor 
agonists 
Liraglutide 
Albiglutide 
Dulaglutide 
Broad Both 1 No Lowers BP 
DPP4 inhibitors 
Sitagliptin 
Saxagliptin 
Improved 
insulin/ 
glucagon 
secretion 
Both 1 No Negligible 
Bile acid 
sequestrants 
Colesevelam Uncertain Prandial 1-2 No 
Lowers 
LDL 
SGIT2 inhibitor 
Canagliflozin 
Dapagliflozin 
Empagliflozin 
↓ renal 
glucose 
reabsorption, 
↑ urinary 
glucose 
excretion 
Both 1 No Negligible 
BP - Blood pressure; CVD - cardiovascular disease; LDL - low-density lipoprotein; SGLT 2 – sodium 
glucose co-transporter 2; SQ - subcutaneous; TG - triglyceride. 
Modified from Melmed S, Polonsky KS, Larsen PR, Kronenberg HM: Williams textbook of 
endocrinology, ed 12, Philadelphia, 2011, Saunders. 
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I.3. Hyperlipidemia 
 Hyperlipidemia is a diverse group of disorders presented with increased in 
triglycerides, total cholesterol, and lipoproteins in the bloodstream that leads to 
atherosclerosis. One of the important risk factor for atherosclerotic cardiovascular 
disease is dyslipidemia. Reductions in cardiovascular disease event rates are 
correlated with lowering of LDL-cholesterol.
11
 Increased levels of cholesterol, 
primarily total cholesterol (TC) and LDL are responsible for the onset of coronary 
heart diseases (CHD).  
Table 4: Major classes of plasma lipoproteins
12
 
Type 
Density 
(g/mL) 
Origin Major Lipids Major Apo 
Size 
(nm) 
Chylomicrons <0.95 Intestine 
85% 
Triglyceride 
B48, AI, 
AIV, E, CI, 
CII, CIII 
~100-
500 
Chylomicron 
remnants 
<1.006 
Derived from 
chylomicrons 
60% 
Triglyceride  
20% Cholesterol 
B48, E 
~80-
125 
VLDL <1.006 Liver 
55% 
Triglyceride  
20% Cholesterol 
B100, E, CI, 
CII, CIII 
30-80 
IDL 
1.006-
1.019 
Derived from 
VLDL 
35% 
Cholesterol  
25% 
Triglyceride 
B100, E 25-35 
LDL 
1.019-
1.063 
Derived from 
IDL 
60% 
Cholesterol  
5% Triglyceride 
B100 18-25 
HDL 
1.063-
1.21 
Liver, 
intestine, 
plasma 
25% 
Phospholipid  
20% 
Cholesterol  
5% Triglyceride 
AI, AII, CI, 
CII, CIII, E 
5-12 
Lp(a) 
1.05-
1.09 
Liver 
60% 
Cholesterol  
5% Triglyceride 
B100, apo(a) ~30 
Apo - apolipoprotein; IDL - intermediate density lipoprotein; LDL - low density 
lipoprotein; Lp(a) - lipoprotein(a); VLDL - very low-density lipoprotein. 
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I.3.a. Overview of hypercholesterolemia and dyslipidemia
12
 
The two major clinical disorders associated with common lipoprotein are very 
elevated triglyceride levels and elevated cholesterol levels. Increased level of 
triglycerides is a risk factor for development of pancreatitis.
13
 Elevated cholesterol 
level due to higher concentrations of low density lipoproteins (LDL), remnant 
lipoproteins and reduced levels of high density lipoproteins (HDL) promote athero-
sclerosis. Clinically hypertriglyceridemia, hypercholesterolemia, combined 
hyperlipidemia due to increased cholesterol and triglycerides, and low HDL syn-
dromes are often seen in patients with lipid disorders. Plasma lipid levels are highly 
dependent on lifestyle. Consumption of high-fat, high-cholesterol diets increase the 
plasma cholesterol. Vigorous exercise reduces both atherogenic particles and 
triglycerides. Serum total cholesterol levels associate with high risk for congestive 
heart disease (CHD) over a broad range. Normal levels are often associated with 
minimal cardiovascular risk. Lipid levels put them at risk for heart disease in most of 
the developed countries worldwide.   
Based on the vascular disease or other cardiac risk factors, The National 
Cholesterol Education Program (NCEP) created a standard for cholesterol levels. 
Treatment is divided according to cardiac risk in population. The NCEP (in 2001) 
classified plasma cholesterol levels lower than 200 mg/dL as desirable, those between 
200 and 240 mg/dL as borderline high, and levels greater than 240 mg/dL as high.14 
Triglyceride levels greater than 500 mg/dL carry a risk of pancreatitis, and those who 
have levels greater than 150 mg/dL are considered as elevated. The Endocrine Society 
used different definitions in 2012. Severe hypertriglyceridemia is associated with 
pancreatitis with triglyceride levels of greater than 2000 mg/dL.15  
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I.3.b. Pathophysiology of Hyperlipidemia
16
 
Lipids have two main pathways of entry into the circulation, viz., the gut 
(exogenous pathway) and the liver (endogenous pathway). Both exogenous and 
endogenous pathways are interconnected by intermediate pathways (reverse 
cholesterol transport pathway and others).  
Figure 2: Overview of exogenous and endogenous pathways of lipid metabolism 
  
CM = chylomicrons; HDL = high-density lipoproteins; IDL = intermediate-density lipoproteins; LDL = 
low-density lipoproteins; VLDL = very–low-density lipoproteins.  
 
I.3.c. Pharmacological treatment for Hyperlipidemia  
Based on the mechanism of action, the currently available lipid-lowering 
agents are classified into statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-
CoA] reductase inhibitors), cholesterol absorption inhibitors such as ezetimibe, niacin, 
fibrates, bile acid sequestrants and PCSK9 (Proprotein convertase subtilisin/kexin 
type 9) inhibitors. These classes of drugs may differ with regard to degree and type of 
lipid lowering action. Agents within the same group may differ in efficacy and side 
effects. Conventional dosing regimens and common adverse effects are presented in 
table 5. The selection of drug is depending on the specific lipid abnormalities and 
comorbidities. Generally, statins are the treatment of choice globally and most 
effective drugs to lower cardiovascular risk. Fibrates or niacin may be more effective 
in lowering of triglycerides. If the monotherapy with statin is not adequate to control 
the lipids, another agent should be used.  
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Table 5: Major drugs used in the management of Hyperlipidemia
16,17
 
Agent 
Starting 
Daily 
Dosage 
Dosage 
Range 
Mechanism Side Effects 
Statins 
Lovastatin  20 mg 10–80 mg 
Decreased 
cholesterol 
synthesis, increased 
hepatic LDL 
receptors, decreased 
VLDL release 
Myalgias, arthralgias, 
high liver enzymes, 
dyspepsia 
Pravastatin 40 mg 10–80 mg 
Simvastatin 
20–40 
mg 
5–80 mg 
Fluvastatin 40 mg 20–80 mg 
Atorvastatin 
10–20 
mg 
10–80 mg 
Rosuvastatin  10 mg 5–40 mg 
Pitavastatin 2 mg 2–4 mg 
Fibrates 
Fenofibrate 
48–145 
mg 
48–145 mg 
Increased LPL 
activity, decreased 
VLDL synthesis 
Dyspepsia, myalgia, 
gallstones, high liver 
enzymes 
Gemfibrozil  1200 mg 1200 mg 
Fenofibric acid  
45–135 
mg 
45–135 mg 
Niacin 
Immediate release 250 mg 
250–3000 
mg Decreased VLDL 
synthesis 
Flushing, high glucose, 
uric acid, high liver 
enzymes Extended release  500 mg 
500–2000 
mg 
Bile Acid Sequestrants 
Cholestyramine  8–16 g 4–24 g 
Increased bile acid 
excretion, increased 
LDL receptors 
Bloating, constipation, 
elevated triglycerides 
Colestipol  2 g 2–16 g 
Colesevelam 3.75 g 
3.75–4.375 
g 
Cholesterol Absorption Inhibitors 
Ezetimibe 10 mg 10 mg 
Deceased intestinal 
cholesterol 
absorption 
High liver enzymes 
Combination Therapies (single pill) 
Ezetimibe/simvastatin 10/20 mg 
10/10–10/80 
mg   
Extended-release 
niacin/simvastatin  
500/20 
mg 
500/20–
1000/20 mg   
PCSK9 Inhibiting Monoclonal Antibodies (subcutaneous) 
Alirocumab 
75 mg 
every 2 
weeks 
75–150 mg 
every 2 
weeks 
Increased hepatic 
LDL receptors 
Injection site reactions, 
nasopharyngitis, upper 
respiratory tract 
infection, influenza, back 
pain 
Evolocumab 
140 mg 
every two 
weeks or 
420 mg 
monthly 
 LDL - low density lipoprotein; LPL - lipoprotein lipase; TG - triglycerides; VLDL - very low-density 
lipoprotein.  
Adapted from Bope ET, Kellerman RD. Conn’s Current Therapy 2017. Philadelphia, PA: Elsevier.   
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Table 6: Metabolic effects of each lipid-lowering agents
18,19
 
Drug Class 
LDL 
Cholesterol 
HDL 
Cholesterol 
Triglycerides 
Statins ↓21%–55% ↑2%–10% ↓6%–30% 
Fibric acids ↓20%–25% ↑6%–18% ↓20%–35% 
Niacin ↓10%–25% ↑10%–35% ↓20%–30% 
Bile acid sequestrants ↓15%–25% 
 
May ↑ 
Cholesterol absorption inhibitors ↓10%–18% 
  
PCSK9 inhibitors ↓39%–62% ↑4%–7% ↓12%–17% 
Adapted from lipoprotein management in patients with cardiometabolic risk, 
consensus statement from the American College of Cardiology Foundation and the 
American Diabetes Association (ACC/ADA) (2008), and American Association of 
Clinical Endocrinologists’ (AACE) guidelines for management of dyslipidemia and 
prevention of atherosclerosis (2012). 
 
I.4. Prevalence of type 2 DM and hyperlipidemia 
DM and hyperlipidemia are coexisting disorders. Type 2 DM is one of the 
most common chronic conditions and its prevalence has increased continuously over 
the past decades. Due to rapid economic growth of China, increased life expectancy 
and altered lifestyle. Both these conditions significantly increased the prevalence of 
type 2 DM.
20-22
 Dyslipidemia is a common comorbidity in diabetes.
22
 Asian and 
European epidemiological studies showed, hyperlipidemia is commonly associated 
with diabetes.
22,23
 
 The World Health Organization (WHO) warns that deaths due to diabetes will 
increase by 80% in some regions, over the period of next ten years. India host to the 
largest diabetes population in the world, with an estimate of approximately 62 million 
individuals
24,25
 and will increase further. Indian Council of Medical Research (ICMR) 
reported that about 5 million peoples affected from Tamil Nadu.
26
 Only 5% of the 
diabetes in the world is type 1 DM and the remaining 95% falls in type 2 DM.
27
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I.5. Rising Prevalence of Diabetes  
Several studies reported that there was an increase of 10-fold (During 1971–
2000), in the incidence of diabetes (from 1.2% in 1971 to 12.1% in 2000) in urban 
parts of India.
28-30
 Between 2003 and 2005, a national survey was conducted in ≥15 
years aged persons, which self-reported the prevalence of diabetes was 7.3% and 
3.2% in the urban and periurban slum areas respectively. But the prevalence was 
significantly lower (3.1%) in rural areas.
31
  
Urban areas have witnessed a 3-4 fold increase in the prevalence of diabetes in 
many regions of the country. The prevalence of DM is reaching a pandemic 
proportion. This could be due to rapid lifestyle transitions and narrowing in the rural-
urban divide in living conditions. Studies from Kerala showed that the prevalence of 
diabetes is higher in the rural population than the urban population.
32,33
 In fact, the 
urbanization rate in Kerala is so rapid, and almost whole Kerala is urbanized.  At 
present, India is the largest rural nation in the world. Urbanization is expected to be 
50% of the country in 2030.
34
  
I.6. The cost of diabetes management  
The cost of diabetes management is very high and it increases many folds 
when there are complications or need of hospitalization or surgery involvement or 
need of insulin therapy. A study showed that the annual median expenditure on 
diabetes care is approximately Rs.10,000 in urban and Rs.6,300 in rural areas.
35
 
Lower income groups spend nearly about 25–35% of their annual income on diabetes 
care. People tend to neglect health care due to the high economic burden. This may 
lead to severe morbidities and early mortality. There is no comprehensive diabetes 
health care program available in India.   
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I.7. Herbal medicine  
 As per WHO Progress Report (No. A44/20, 22 March 1991, WHO, Geneva, 
1991) traditional medicines including herbal drugs comprise therapeutic practices and 
have been used for hundreds of years. Herbal medicines usage and research in 
Ayurveda sector is considerably increased in recent years. But the herbal medicines 
are existed before the development of modern medicines and still it is in use. 
 The traditional preparations are comprised with medicinal plants, minerals, 
and organic matter. Herbal medicines are used since last 5000 years. The country 
which use more herbal medicines include India, China, Egypt, Greek, Roman and 
Syria. The evidence of herbal medicines usage is well described in Indian Veda’s such 
as Rigveda, Samaveda and Atherveda. Thus, the herbal/traditional medicines are 
therefore, derived from rich traditional and ancient civilizations of scientific heritage. 
 Traditional herbal medicine practice is being followed throughout the globe in 
the form of indigenous medicine. The use of medicinal plants for healing human 
ailments goes with the evolution of human civilization and it can be a basis of origin 
for modern medicine.
36
  A worldwide boost received by the herbal medicines when 
the WHO encouraged developing countries to use traditional medicine systems to 
fulfil the needs unmet by modern systems.
37
  
 Herbal medicine is still the mainstay of about 75–80% of the world 
population, mainly in the developing countries, for primary health care because of 
better cultural acceptability, better compatibility with the human body and lesser side 
effects.
38,39
 The herbal drugs are economic, locally available and believed to have no 
side effects.
40
 Herbal medicines are used to treat or alleviate maximum every possible 
medical condition.    
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Table 7: An overview of common herbal medicine used in different medical   
conditions 
Herbal name Conditions used 
Aloe Topically for minor burns, sunburns, skin irritation or 
inflammation 
Arnica Topically for bruises, sprains, sore muscles and joints 
Chamomile tea Stomach  upset, heartburn, indigestion and colic 
Comfrey Topical poultice only, for bedsores, diabetic ulcers, 
certain spider bites and staph infections contracted on 
tropical beaches 
Dong quai (women) 
Ginseng (men/women) 
To improve general health and stamina – in this 
application, these are known as tonics  
Echinacea Cold, flu, sore throat 
Garlic  Possibly reduces cholesterol and blood pressure. 
To treat fungal infections and colds 
Ginger Nausea and motion sickness and as an anti-
inflammatory 
Mullein Chest congestion and dry, bronchial coughs 
Passionflower Non-sedating relaxation 
Peppermint oil   Irritable bowel syndrome and other chronic intestinal  
ailments 
Peppermint tea Indigestion, nausea and other digestive problems 
Tea tree oil Topically for fungal infections such as athlete’s 
foot and fungal infections of the toenails and fingernails 
Turmeric To combat inflammation and protect against cancer and 
Alzheimer’s disease 
Valerian Sleeping problems 
 
I.7.a. Why Herbal medicine? 
 Herbal medicines are being used by about 80% of the world population 
primarily in the developing countries for primary health care. They have stood the test 
of time for their safety, efficacy, cultural acceptability and lesser side effects. The 
chemical constituents present in them are a part of the physiological functions of 
living flora and hence they are believed to have better compatibility with the human 
body. Former literature mentioned about the use of herbal medicines for the treatment 
of age-related diseases such as alzheimer's, diabetic-wounds, osteoporosis, immune 
related and liver disorders, etc. These drugs are prepared by eco-friendly processes 
using from renewable resources and will bring economic prosperity. 
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I.7.b. Herbal Medicines in India  
 India is sitting on a gold mine of well-recorded and well-practiced knowledge 
of traditional herbal medicines. Ayurveda, Siddha and Unani systems of medicine is 
about $ 1billion with a meager export of about $ 80 million. India is having over 
45,000 plant species and one of the 12 mega biodiversity centres. Its diversity is 
unmatched due to the presence of 16 different agroclimatic zones, 10 vegetative zones 
and 15 biotic provinces.
41
 About 17000 – 18000 species of flowering plants are found 
in India, out of which 6000 –7000 are estimated to have potential medicinal 
properties.
42
 The country has 23000 fungi, 2500 algae, 1600 lichens, 1800 bryophytes 
and 30 million micro-organisms.
43
  
Many Indian cultures and documented Indian systems of medicine such as 
Ayurveda, Siddha, Unani, and Homeopathy described the usage of these medicinal 
plants. Approximately 960 species are estimated to be in trade and about 178 species 
have annual consumption of 100 metric tons. These medicinal plants are not only 
constituting a major resource base for the traditional medicine and herbal industry. 
Also, it provides livelihood and health security to a large section of Indian population. 
AYUSH industry is an approximate estimation of 80 - 90 billion in Indian rupee 
value.
42
 There is an evidence of irrational usage of herbal drugs despite of all 
developments in AYUSH.
44
  
There is much evidence of irrational use of herbal drugs in the community. An 
outbreak of veno-occlusive disease with 42% mortality (67 cases of recoded death) 
occurred in Central India due to consumption of cereals mixed with seeds of a plant 
(Crotalaria species) containing pyrrolizidine alkaloid.
45
 Hence the phytochemical 
screening, isolation and standardization of active ingredients and pre-clinical studies 
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plays an important role before using herbal medicines in humans. Researchers 
continuously work on different herbal plants with different indications to find out the 
better active compounds with lesser side effects.  
 In India, the herbal drug market include Ayurveda, Siddha and Unani systems 
of medicine is about $ one billion and the export of plant-based crude drugs is around 
$ 80 million (Sectoral Study on Indian Medicinal Plants – Status, Perspective and 
Strategy for Growth, Biotech Consortium India Ltd, New Delhi, 1996). Herbal 
medicines current market is estimated at about $ 80–250 billion in USA and also in 
Europe.
46
 
 The basic requirements for gaining entry into developed countries include:     
(i) well-documented traditional use, (ii) single plant medicines, (iii) medicinal plants 
free from pesticides, heavy metals, etc., (iv) standardization based on chemical and 
activity profile, and (v) safety and stability. However, mode of action studies in 
animals and efficacy in human will also be supportive. 
 Herbal medicines gained an extraordinary amount of popularity in the past 
several decades. High usage of herbal medicines is often in immigrants and patients 
with diseases such as difficult-to-treat which include advanced cancer and acquired 
immunodeficiency syndrome (AIDS). Approximately 30% of the general population 
use the herbal products.
47-49
  
 Consumers often perceive herbals as more “natural” and thus “safer” and 
“harmless” despite many examples of toxicity associated with their use. Glover DD et 
al., documented 45% herbal medicine use during some point of the pregnancy in one 
study.
50
 Some studies reported, emergency department patients are also frequent users 
of herbal products.
51-53
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 Though the herbal products are used for their medicinal value, they are 
classified under dietary supplements and not regulated as medications.
48,53,54
  
 Regulation of dietary supplements is limited. Manufacturers are responsible 
for the safety, efficacy and quality of medicines. There are thousands to hundreds of 
thousands of potential herbal products which are used as dietary supplements which 
are lying with the FDA for proving efficacy and safety.
54-56
  
 Limited studies are looking at the efficacy of herbal products with few 
randomized, controlled trials. The National Institutes of Health sponsored several 
high-profile randomized placebo-controlled trials assessing the efficacy of several 
well-known herbals: St. John’s wort for depression, glucosamine–chondroitin sulfate 
for arthritis of the knee, hawthorne extract for congestive heart failure, saw palmetto 
for benign prostatic hypertrophy, echinacea for the common cold and ginko biloba for 
dementia onset. Unfortunately, none of these trials have shown that the herbal 
treatment to be effective.
57-62
 Thus, the selection of right herbals to the right 
disorder/disease plays an important role in the use of herbal products for treatment. 
Very few studies are evaluating the side effects, drug interactions and toxicity of the 
herbal products.  
Most of the herbal products have some direct pharmacological effect. The 
potency of these agents is usually limited. However, the toxicity and side effects from 
the direct actions are relatively uncommon.
57-64 
Four major types of toxicological 
problems are usually associated with the use of herbal products, viz; the 
misidentification of an herbal plant/toxicity resulting from a substituted plant, 
contamination with non-herbal toxic material, direct toxicity or overdose and drug-
herbal interactions.
65
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II. AIM AND OBJECTIVES 
 L. aspera was investigated and reported for a wide spectrum of biological 
activities which included anti-inflammatory, larvicidal, fungicidal, antimicrobial, 
hepatoprotective, anti-arthritic, hypoglycemic, antioxidant and cytotoxic activities. 
The biological activities were attributed to the presence of phytoconstituents such as 
flavonoids, alkaloids, essential oils, phenolic components, tannins, etc. To the best of 
our knowledge from review of literature, no study has ever compared the anti-
diabetic, anti-hyperlipidemic and antioxidant activity of L. aspera leaves in type-2 
DM with two different solvent extracts. Hence, the present study was designed to 
evaluate the pharmacological activities of leaves of L. aspera using polar and non-
polar solvent extracts in rats with type-2 DM. 
This study is designed to investigate the following: 
 Different phytoconstituents present in the polar and non-polar solvent extracts 
of L. aspera leaves. 
 Identification and isolation of active constituents present in the polar and non-
polar solvent extracts of L. aspera leaves using TLC and HPTLC techniques. 
 In vitro and in vivo antioxidant activity of polar and non-polar solvent extracts 
of L. aspera leaves. 
 In vitro anti-diabetic activity of polar and non-polar solvent extracts of           
L. aspera leaves. 
 Acute oral toxicity of polar and non-polar solvent extracts of L. aspera leaves. 
 Anti-diabetic activity of polar and non-polar solvent extracts of L. aspera 
leaves. 
 Anti-hyperlipidemic activity of polar and non-polar solvent extracts of           
L. aspera leaves. 
 Effect of L. aspera leaves on stress induced depression associated with DM. 
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III. REVIEW OF LITERATURE 
III.1. Plant Review 
 Leucas aspera (Willd.) Link (L. aspera) within the Leucas genus belongs to 
Labiatae (Lamiaceae) family and commonly found throughout India and Philippines 
as well as in the plains of Mauritius and Java. It is a very common weed in India and 
it is an annual plant grows up to 15-60 cm height.
 
Depending on the region it has 
many different vernacular names. L. aspera is most commonly known as Thumbai.
66 
The juice of L. aspera leaves are used as remedy for chronic skin eruptions, chronic 
rheumatism and psoriasis.
67
 In villages L. aspera leaves are used as insecticides and 
mosquito repellent. 
L. aspera leaves: Leaves are opposite, subsessile or short petioled, linear or narrowly 
oblong- lanceolate, entire or distantly crenate, obtuse, narrowed at the base.
68
 Plants 
can grow up to 8 cm (3.1 inch) in length, and 1.25 cm (0.49 in) in broad. The length 
of petioles is typically 2.5 - 6 mm in long. The leaf epidermis is covered with a thick 
waxy cuticle and is traversed with stomata.
69
 
 L. aspera stem: The stem is quadrangular, much branched, hispid or scabrid
68
 and 
contains a wide stele. The xylem tissue is organized in radial position and the 
parenchymatous phloem tissue is very narrow in younger stems. The phloem tissue 
widens as the stem grows and it appears on both sides of xylem tissue.
69
 
L. aspera roots: The roots are narrow and closely packed with epidermal cells. The 
epidermal cell wall is very thin, straight and flattened. The parenchyma in the cortex 
contains thick walls. Polygonally shaped parenchyma cells are present in the stem.
69
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III. 1.1. Synonyms for the plant Leucas aspera (Willd) Link
70
 
Leucas dimidiata (Roth) Spreng. 
Leucas minahassae Koord., nom. nud. 
Leucas obliqua Buch.-Ham. ex Dillwyn 
Leucas plukenetii (Roth) Spreng. 
Phlomis aspera Willd. 
Phlomis dimidiata Roth 
Phlomis esculenta Roxb. 
Phlomis obliqua Buch.-Ham. ex Hook.f. 
Phlomis plukenetii Roth 
 
III. 1.2. Common names of Leucas aspera (Willd.) Link
70
 
Language  Name 
Bengali : Ghal Ghase 
English  : Thumba, Common Leucas 
Hindi : Chota Halkusa, Gopha, Gophaa 
Irula : Thubmai 
Kannada : Thumbe gida, Tumbe Guda 
Konkani : Tumbo 
Malayalam : Chiruthumba, Tumba, Thumba 
Manipuri : Mayanglambum 
Marathi  : Tamba 
Oriya : Bhutamari 
Others  : Pansi-pansi, Thumbai, Common Leucas 
Sanskrit : Dronapushpi 
Tamil  : Thumbai 
Telugu : Tummachettu 
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III. 1.3. Scientific classification of L. aspera 
Kingdom   :  Plantae   
Subkingdom   :  Angiosperms  
Division   :  Eudicots  
Order    :  Lamiales                       
 Family   :  Lamiaceae                         
Genus     :  Leucas   
Species  :  L. aspera 
Botanical name  :  Leucas aspera 
 
Figure 3: Pictorial presentation of Leucas aspera (Willd.) Link 
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III. 2. Review of published literatures on L. aspera  
 L. aspera is a well-known medicinal plant in Indian medicinal system
67
 and it 
was evaluated for many phytochemicals and biological activities.
69,71
 The species 
were investigated for anticataractogenic, anticancer, larvicidal, antimicrobial and 
antibacterial, anti-ulcer, antipsoriatic, anti-hyperglycemic, thrombolytic and cytotoxic, 
anti-inflammatory, hepatoprotective and anti-oxidant activities. Couple of compounds 
have been isolated and characterized from the L. aspera species.  
III. 2.1. Anticataractogenic activity of L. aspera 
 Sundararajan M et al.
72
 evaluated the possible anticataractogenic activity of 
ethanol extract of L. aspera root in cultured Wistar rat lenses. The authors 
investigated the ethanol extract of L. aspera in Dulbecco's modified Eagle's medium 
(DMEM). The L. aspera root extract exhibited a slight degree of opacification    
(Grade +) after 24 hours of incubation. The activities of superoxide dismutase (SOD), 
glutathione peroxidase (Gpx), catalase (CAT) and reduced glutathione were assessed. 
The results of this study suggested that exposure to ethanol extract of L. aspera 
prevented the lenticular opacification based on the enzymatic antioxidants activities, 
levels of reduced glutathione and malondialdehyde, genes expression encoding αA 
and βB1-crystallins and crystallin proteins level.  
III. 2.2. Anticancer activity of L. aspera 
 Mohan A et al.
73
 assessed the nanoparticles and crude methanol extract of       
L. aspera against cytotoxicity and Cell Migration Retardation in PC3 Prostate Cancer 
Cells under in vitro models. The in vitro cytotoxicity of L. aspera nanoparticles were 
concentration and time dependent in PC3 prostate cancer cells. This in vitro          
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anti-cancer activity was established by cell aggregation study, cellular uptake study, 
cell migration study and hemolysis assay.   
III. 2.3. Larvicidal activity of L. aspera 
 Suganya G et al.
74
 evaluated the silver nanoparticles synthesized from             
L. aspera leaf extract against dengue vector Aedes aegypti. This study investigated the 
larvicidal potential of crude and synthesized silver nanoparticles from aqueous leaf 
extract of L. aspera. against 4th instar larvae of A. aegypti. The larvae were exposed 
to different concentrations of extract and synthesized AgNPs for 24 hours. The study 
results were recorded from UV visible spectrometer, Fourier transform infrared 
(FTIR), X-ray diffraction (XRD) and scanning electron microscopy (SEM). The study 
results suggested that the synthesized AgNP from leaf extract had shown higher 
larvicidal potential compared to crude solvent extract.  
 Elumalai D et al.
75
 evaluated the larvicidal activity of whole plant methanol 
extract and fractions of L. aspera against Aedes aegypti, Anopheles stephensi, and 
Culex quinquefasciatus. The larvae were exposed to fractions obtained from L. aspera 
with the varying concentrations (ranging from 1.25, 2.25, 5, 10, and 20 ppm) and 
isolated Catechin. After the exposure (24 h), the mortality of larva was assessed. Out 
of 8 fractions, 4 from hexane extraction showed potent larvicidal activity at 20 ppm 
concentration against tested mosquito species. Pronounced larvicidal activity was 
observed at low concentrations of isolated catechin. The authors used GC-MS, FTIR, 
1H NMR, and 13C NMR elucidate the structure of the isolated compound. 
 Kovendan K et al.
76
 investigated the larvicidal and pupicidal effect of            
L. aspera against malarial vector using whole plant ethanol extract. They also 
evaluated the Bacillus sphaericus (B. sphaericus) against malarial vector and 
Anopheles stephensi Liston (A. stephensi). The activity was carried out on first to 
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fourth instar-larvae and pupae of the mosquito A. stephensi which was laboratory-
reared. The larvicidal and pupicidal effect was noted after exposing (24 h) to plant 
extract. Highest mortality was occurred in first to fourth instar-larvae and pupae with 
whole plant ethanol extract of L. aspera. The study results suggested that the ethanol 
extracts of L. aspera and B. sphaericus are potentially controlled the malarial vector               
A. stephensi. 
III. 2.4. Antimicrobial and antibacterial activity of L. aspera 
Saritha K et al.
77
 compared the antibacterial activity of 95% alcohol extract of  
L. aspera (whole plant) along with other plants viz. Hemidesmus indicus (L.) R. Br. ex 
Schult (root), Tridax procumbens (L.) R. Br. ex Schult (whole plant) and Plumbago 
zeylanica L (root). The authors concluded that the antibacterial activity is time and 
concentration dependent.  
Rahman MA et al.
78
 evaluated the antioxidant and antioxidant effect of           
L. aspera using whole plant extract. The study also investigated the Cytotoxic 
properties of L. aspera against vincristine sulfate. The plant was collected from 
Chittagong, Bangladesh. The plant extract showed highest zone of inhibition against 
both the Gram positive organisms (B. subtilis and B. megaterium) and Gram negative 
organisms (P. aeroginosa, V. choleriae and S. dysenteriae). Gram positive strains 
were more sensitive to L. aspera extract compared to Gram negative strains. But the 
extract showed lowest antibacterial activity against S. typhi. The cytotoxic effect of    
L. aspera was similar to that of vincristine. The anti-oxidant effect was evaluated by 
DDPH scavenging activity which showed a better antioxidant activity compared to 
standards used. 
 Chew AL et al.
79
 compared the antioxidant activity and antibacterial activity 
of methanol extract of different parts (root, flower, leaf and stem) of L. aspera with 
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commercially available agents. In addition, the toxicity effect was also studied using 
L. aspera root extract. The plane was collected from Malaysia. The antibacterial effect 
was tested against Staphylococcus aureus, Escherichia coli, Pseudomonas 
aeruginosa, Salmonella typhimurium, Salmonella choleraesuis, and Shigella flexneri. 
The antioxidant activity was tested by free radical scavenging method.  In conclusion, 
the study demonstrates that methanol extracts from various parts of L. aspera are 
different in their antioxidant and antimicrobial effects. The study results showed root 
extract possess the highest antioxidant and antimicrobial activity among the different 
parts used. Toxicity study showed that the root extract was nontoxic. 
 Mangathayaru K et al.
80
 demonstrated the antimicrobial activity of methanol 
extract of L. aspera flowers. The fractions of alkaloidal residue and flower juice were 
tested for antimicrobial activity. The results showed better antibacterial activity, 
among methanol fraction of alkaloidal residue from L. aspera showed better activity 
than crude extract. 
III. 2.5. Antiulcer activity of L. aspera 
 Reddy MK et al.
81
 investigated the antiulcer activity of L. aspera Spreng, by 
Shay rat ulcer and aspirin induced ulcer. Ninety percent alcoholic extract of L. aspera 
Spreng showed potent antisecretory activity with a significant reduction in gastric 
acid secretion (free acid and total acid). 
III. 2.6. Antipsoriatic activity of L. aspera 
 Singh SK et al.
82
 assessed the in vitro antipsoriatic activity of selected well-
known Indian medicinal plants which included Phyllanthus simplex Retz. 
(Phyllanthaceae), Crotolaria juncea Linn. (Leguminosae), Leucas aspera Linn. 
(Lamiaceae), and Vitex glabrata R.Br. (Verbenaceae). This investigation showed 
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promising skin keratinocyte antiproliferative activity. Antipsoriatic activity mediated 
by an antioxidant mechanism was shown by the inhibitory action against nitric oxide 
production and lipid peroxidation in HaCaT cells. Among the plant extracts used, 
petroleum ether extract of C. juncea and ethanol extract of L. aspera showed 
significant activity. 
III. 2.7. Antihyperglycemic activity of L. aspera 
 Mannan A, et al.
83
 evaluated the antihyperglycemic activity of L. aspera    
(leaf, stem) and Lannea Coromandelica (Houtt.) bark in Mice. The plants were 
collected from Dhaka, Bangladesh and extracted with methanol. Swiss albino mice 
were used for the experimental study. Methanol extract of L. aspera leaf and stem 
were tested in glucose-challenged mice. Both the extracts showed dose-dependent 
anti-hyperglycemic effect. The effect of leaf extract of L. aspera was slightly better 
than the stem extract. 
 Gupta et al.
84
 compared the anti-diabetic and anti-hyperglycemic activity of 
ethanol extract of L. aspera with Pithecellobium bigeminum seeds in streptozotocin 
and alloxan induced-diabetic rats. Sprague-Dawley rats were used for the 
experimental studies. The authors reported, both the L. aspera P. bigeminum 
exhibited significant anti-hyperglycemic activity in both the streptozotocin and 
alloxan-induced diabetes. Improvement in body weight, lipid profiles and 
regeneration of beta cells in pancreas also observed in the extract treated groups. 
 Tukaram et al.
85
 evaluated the ethanol extract of L. aspera leaves on alloxan-
induced type-1 DM. The study found that the crude extract ameliorates the 
hyperglycemia in alloxan-induced rats. 
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III. 2.8. Thrombolysis and cytotoxicity effect of L. aspera 
 Rahman MA et al.
86
 compared thrombolytic and cytotoxic effect of six 
Bangladesh plants which included L. aspera, Senna sophera L. Roxb., Ageratum 
conyzoides L., Leea indica (Burm.f.) Merr., Clausena suffruticosa, and Solanum 
torvum Swartz under in vitro models. This study showed L. aspera.  C. suffruticosa 
and Leea indica possessed effective thrombolytic properties than Senna sophera and 
S. torvum. None of these plant extracts showed any cytotoxic effect compared to 
positive control.   
III. 2.9. Anti-inflammatory and adjuvant arthritis activity of L. aspera 
 Kripa KG et al.
87
 investigated the anti-inflammatory activity of ethanol extract 
of L. aspera in adjuvant arthritis. In this study Freund's adjuvant was served to induce 
arthritis in animals. Tumor necrosis factor (TNF-α), Interleukin 2 (IL2), Cathepsin D 
and C-reactive protein (CRP) levels were measured. Enzyme activities viz. SOD, 
CAT and GPx were estimated. Ethanol extract of L. aspera exhibited significant anti-
inflammatory and antioxidant activity. No mortality was observed in doses up to 2000 
mg/kg body weight. This study highlighted the anti-inflammatory and antioxidant 
potential of L. aspera. The activity could be due to the presence of phytochemicals 
such as catechins, flavonoids, phytosterols and phenolic compounds. 
 Reddy MK et al.
88
 investigated the aqueous and alcoholic extracts of               
L. aspera for anti-inflammatory (paw edema method) and mast cell degranuatlion     
(in vitro). Proprancolol and Carbachol were used for induction of inflammation and 
cell degranulation in experimental animals. Both the extracts of L. aspera effectively 
prevented the acute and chronic inflammation.  
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III. 2.10. Hepatoprotective and antioxidant activity of L. aspera 
 Banu S et al.
89 
investigated the hepatoprotective and antioxidant activity of 
whole plant aqueous extract of L. aspera in d-galactosamine (D-GalN)-induced 
hepatotoxicity in rats. Also, the authors studied the protective effect on microsomal 
drug metabolizing enzymes (MDMEs). Hepatoprotective activity was assessed by 
biochemical and histopathological studies. Protective effect against MDMEs was 
assessed by hexobarbitone-induced sleeping time model. The extract of L. aspera 
significantly protected the liver. The levels of antioxidant enzymes viz. superoxide 
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) were 
significantly increased and lipid peroxidation (LPO) level was decreased in the liver.   
III. 2.11. Antimalarial activity of L. aspera 
Kamaraj C et al.
90
 investigated in vitro antimalarial activity of twenty-four 
plants against Plasmodium falciparum. The authors also assessed the cytotoxicity 
against HeLa cell line. The results of this study revealed, Aegle marmelos leaf, 
(methanol extract), Lantana camara leaf, (ethyl acetate extract), L. aspera flower 
(ethyl acetate extract), Momordica charantia leaf (ethyl acetate extract), Phyllanthus 
amarus leaf (ethyl acetate extract) and Piper nigrum seed (ethyl acetate extract) have 
good antimalarial activity against Plasmodium falciparum.  
Bagavan A et al. 
91
 tested the hexane, chloroform, ethyl acetate, acetone, and 
methanol extracts of Citrus sinensis (peel), L. aspera, Ocimum sanctum, Phyllanthus 
acidus (leaf), Terminalia chebula (seed) against chloroquin sensitive Plasmodium 
falciparum. The study results revealed, phytocomponents present in the extracts of 
L. aspera, P. acidus, and T. chebula have antiplasmodial activity have good 
antiplasmodial activity. 
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IV. SCOPE AND PLAN OF WORK 
L. aspera is one of the well-known herbs in Indian medicine system. The plant 
was evaluated for many pharmacological properties which include larvicidal, anti-
ulcer, anti-inflammatory, antimicrobial, anti-hyperglycemic, anti-arthritic, anti-
oxidant, cytotoxic and anti-cataractogenic activities, and many more. However, none 
of these studies compared the combined anti-diabetic, anti-hyperlipidemic and anti-
oxidant activities of two different solvent extracts (polar and non-polar) in type 2 DM. 
In this current study, we planned to investigate the combined anti-diabetic, anti-
hyperlipidemic in vitro and in vivo anti-oxidant activities of L. aspera leaves polar 
and non-polar solvent extracts in type 2 DM and hyperlipidemia induced rats. In 
addition, we also planned to evaluate the effect of L. aspera leaf in depression 
associated with diabetes condition.  
 The plant will be collected from the villages of Dindigul district. 
 After collection, the authentication of plant will be obtained from a certified 
Botany centre or from a University.  
 After obtaining authentication, leaves will be isolated, cleaned and dried at 
sunshades. Then it will be stored in a zip-lock cover for further use. 
 Five different solvents with increase in polarity will be used for extraction 
purpose. This is to look, whether polarity of the solvents produce any major 
difference in extraction.  
 Once the extracts are ready, a complete preliminary phytochemical screening 
will be performed on all the five extracts.  
 TLC and HPTLC studies will be performed for isolation and identification of 
compounds. 
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 A quantitative estimation of total flavonoids, alkaloids, phenolic compounds 
and tannins will be performed on all the five solvent extracts.  
 We plan to investigate the anti-oxidant activity of all the five solvent extracts 
under different in vitro models. 
 Also, we will evaluate the anti-diabetic activity of polar and non-polar solvent 
extracts under in vitro models before the animal experiments. The polar and 
non-polar solvent will be selected based on the results of phytochemical 
screening, chromatographic studies and in vitro antioxidant activities. 
 An acute toxicity study of selected polar and non-polar solvent will be carried 
out based on OECD 423 guidelines. The doses will be fixed for the treatment 
purpose, based on acute toxicity study results. 
 After an acute toxicity study, animals will be randomly allotted in to 7 groups 
containing six animals in each group. 
 The experimental type 2 diabetes and hyperlipidemia will be induced in same 
animal using a high fat diet and streptozotocin. 
 Two doses (low dose and high dose) of extracts will be used for the treatment. 
A four-week course of treatment will be given in experimental animals to 
check the anti-diabetic and anti-hyperlipidemic effects of polar and non-polar 
solvent extracts of L. aspera leaves. Glibenclamide (anti-diabetic) and 
Atorvastatin (anti-hyperlipidemic) will be used as standard drug for treatment. 
 Anti-depression studies will be performed before and after the treatment to 
check the effect of L. aspera leaves on depression associated with type 2 DM.   
 At the end of the study, animals will be scarified by euthanasia method and 
organs will be harvested for in vivo anti-oxidant enzymatic activities.  
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V. MATERIALS AND METHODS 
V.1. Plant collection and authentication   
 Well grown plants of L. aspera were collected from Kandappakottai Village, 
Dindigul district, Tamil Nadu, India, between November 2014 and January 2015. The 
plant was authenticated (PARC/2014/2272; Appendix-1) by Prof. P Jayaraman, 
Director, Institute of Herbal Botany and Anatomy Research Centre, Tambaram, 
Chennai. Then leaves were isolated, cleaned and dried at sun shadows. Dried leaves 
were crushed in to powder and passed through pharmaceutical sieve no 40 and 80. 
Any materials which is passed through sieve-40 and retained at sieve-80 were 
collected and used for the extraction. 
V.2. Solvent selection / used 
 Polar solvents will dissolve polar compounds and non-polar compounds, 
whereas non-polar solvent will dissolve only non-polar compounds. Based on this 
theory and literatures we had selected five different solvents with increasing in 
polarity for extraction process, which included petroleum ether, ethyl acetate, 
chloroform, ethanol and isopropyl alcohol.  
 Very polar solvents: Methanol > Ethanol > Isopropanol 
 Moderate Polar solvents: Acetonitrile > Ethyl acetate > Chloroform > 
Dichloromethane > Diethyl ether > Toluene 
 
 Non-polar solvents: Cyclohexane > Petroleum ether > Hexane > Pentane 
V.3. Preparation of crude extracts 
V.3.1. Preparation of petroleum ether extract 
Hot continuous extraction process (Soxhlet apparatus) was used for petroleum 
ether extraction. Six hundred grams of powdered leaf extracted with 2.5 L of 
petroleum ether (60 - 80
0 
C). Excess solvent was then removed by distillation method.  
Materials and Methods 
31 
 
Crude extract was dried at vacuum desiccator and dried extract has been collected and 
stored in a glass bottle at -20
0
C until used. 
V.3.2. Preparation of ethyl acetate extract  
Cold maceration technique was used for the preparation of ethyl acetate 
extract. Two hundred grams of powdered leaf was soaked in 1.0 L of ethyl acetate for 
72 hours. After soaking, the mixture was heated at 30±5
0
C for 60 min. Heated 
solution was cooled to room temperature and filtered through muslin cloth and 
Whatman filter paper. Excess solvents were then removed by distillation method and 
allowed to evaporate at room temperature.  Dried crude extracts were collected and 
stored in an individual glass bottles at -20
0
C for further studies. 
V.3.3. Preparation of chloroform extract  
Cold maceration technique was used for the preparation of chloroform extract. 
Two hundred grams of powdered leaf was soaked in 1.0 L of ethyl acetate for 72 
hours. After soaking, the mixture was heated at 30±5
0 
C for 60 min. Heated solution 
was cooled to room temperature and filtered through muslin cloth and Whatman filter 
paper. Excess solvents were then removed by distillation method and allowed to 
evaporate at room temperature.  Dried crude extracts were collected and stored in an 
individual glass bottles at -20
0 
C for further studies. 
V.3.4. Preparation of ethanol extract  
Cold maceration technique was used for the preparation of ethyl acetate 
extract. Six hundred grams of powdered leaf was soaked in 2.5 L of ethyl acetate for 
72 hours. After soaking, the mixture was heated at 30±5
0
C for 60 min. Heated 
solution was cooled to room temperature and filtered through muslin cloth and 
Whatman filter paper. Excess solvents were then removed by distillation method and 
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allowed to evaporate at room temperature.  Dried crude extracts were collected and 
stored in an individual glass bottles at -20
0
C for further studies. 
V.3.5. Isopropyl alcohol extraction  
Cold maceration technique was used for the preparation of isopropyl alcohol 
extract. Two hundred grams of powdered leaf was soaked in 1.0 L of ethyl acetate for 
72 hours. After soaking, the mixture was heated at 30±5
0
C for 60 min. Heated 
solution was cooled to room temperature and filtered through muslin cloth and 
Whatman filter paper. Excess solvents were then removed by distillation method and 
allowed to evaporate at room temperature.  Dried crude extracts were collected and 
stored in an individual glass bottles at -20
0
C for further studies. 
V.4. Qualitative screening of phytochemicals presents in L. aspera leaves 
 All the five crude extracts were screened for the presence of phytoconstituents. 
The extracts were tested for flavonoids, alkaloids, carbohydrates & reducing sugars, 
saponins, glycosides, tannins, steroids, proteins & amino acids, tri terpenoids and 
fixed oils with all respective testing procedures as described in the textbook by 
Harborne JB (eds.).
92
  
V.4.1. Test for alkaloids 
Small quantity of each solvent extract was dissolved in dilute hydrochloric 
acid. The solution was filtered and the filtrate was used for the following tests. 
a. Dragendorff’s test:  One mL of filtrate was added to 1 mL of potassium 
bismuth iodide solution (Dragendorff’s reagent). Formation of an orange red 
colour precipitation indicates the presence of alkaloids. 
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b. Mayer’s test: One mL of filtrate was added to 1 mL of potassium mercuric 
iodide solution (Mayer’s reagent). Formation of a Whitish yellow colour 
precipitate indicates the presence of alkaloids. 
c. Hager’s test: One mL of filtrate was added to 3 mL of saturated aqueous 
solution of picric acid (Hager’s reagent). Formation of yellow colour 
precipitate indicates the presence of alkaloids. 
d. Wagner’s test: One mL of filtrate was added to 2 mL of iodide in 
potassium iodide (Wagner’s reagent). A reddish-brown colour precipitate 
formation indicates the presence of alkaloids. 
e. Tannic acid test: One mL of filtrate was added to 1 mL of 10% tannic acid 
solution. Buff colour formation indicates the presence of alkaloids. 
V.4.2. Test for flavonoids 
a. Shinoda’s test: An aliquot quantity of crude extract was dissolved in 
alcohol and 3-4 pieces of magnesium ribbon were added. Addition of few 
drops of concentrated hydrochloric acid produced cherry red colour indicates 
the flavonoids presence. 
b. Alkaline reagent test: Small quantity of crude extract was treated with 
sodium hydroxide. Yellow colour formation indicates the presence of 
flavonoids. 
c. Lead acetate test: Little amount of crude extract was treated with lead 
acetate solution. Yellow colour solution formed and disappeared on addition 
of an acid indicates the presence of flavonoids. 
Materials and Methods 
34 
 
d. Sulphuric acid test: On addition of concentrated sulphuric acid to crude 
extracts produced yellow or orange colour indicates the presence of 
flavonoids.     
V.4.3. Test for carbohydrates and reducing sugars 
Small quantity of extract was dissolved in distilled water. This solution was 
used for the following tests.
 
a. Molisch’s test:  Two mL of extract solution was added with 1 mL of          
α- napthol solution and concentrated sulphuric acid through sides of the test 
tube. A reddish violet colour ring formation at the junction of two liquids 
indicates the presence of carbohydrates.
 
b. Fehling’s test: One mL of extract solution was added with equal quantities 
of Fehling’s solution A and B. Brick red precipitate formation upon heating 
indicates the presence of reducing sugars.
 
c. Benedict’s test: One mL of extract solution was added to 5 mL of 
Benedicts reagent and boiled for 2 minutes. Red precipitate formation upon 
cooling shows the presence of sugars. 
 
d. Tollen’s test: One mL of extract solution was added with 2 mL of Tollen’s 
reagent and boiled. A silver mirror formation inside the wall of the tube which 
indicates the presence of aldose sugar.
 
e. Seliwanoff’s test:  Small amount of crude extract was treated with 
hydrochloric acid and resorcinol. Upon heating formation of red colour shows 
the presence of glucose.
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f. Bromine water test: Little quantity of extract solution was added to 
bromine water. Decolonization indicates the presence of aldose sugar.
 
V.4.4. Test for saponins 
a. Foam test: Small amount of extract was diluted with 20 mL of distilled 
water in a graduated cylinder and shaken well for 15 min lengthwise. 
Formation of a foam layer (about 1 cm) indicates the presence of saponins. 
b. Lead acetate test: One mL of extract solution was treated with 1% lead 
acetate solution. A white precipitate formation indicates the presence of 
saponins. 
c. Hemolytic test: Drop of extract solution was added to a drop of blood 
placed on glass slide. Hemolytic zone appearance shows the presence of 
saponins. 
V.4.5. Test for glycosides
 
a. Legal’s test: Aliquot quantity of extract was dissolved in pyridine and 
sodium nitroprusside solution. Pink red to red colour formation shows the 
presence of glycosides. 
 
b. Baljet test: One mL of the extract solution was added to 1 mL of sodium 
picrate solution. Change of yellow to orange colour indicates the presence of 
glycosides.
 
c. Keller- killiani test: Extract was dissolved in ethanol and 0.5 mL of strong 
lead acetate solution and filtered. The filtrate was shaken well with 5 mL of 
ChCl3. The chloroform layer is separated in a porcelain dish and solvent was 
evaporated gently. Cooled residue was dissolved in 3 mL of glacial acetic acid 
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containing 2 drops of FeCl3 solution. This mixture was carefully transferred to 
the surface the concentrated sulphuric acid (2 mL). A reddish-brown layer 
forms at the junction of two liquids and the upper layer slowly become bluish 
green then darkened with standing.
 
d. Borntrager’s test:  Few mL of dilute sulphuric acid was added to the 
extract and the solution was boiled and then filtered. To the filtrate chloroform 
was added and the layer was treated with 1 mL of ammonia. A red colour 
(ammonical layer) formation shows the presence of anthraquinone glycosides.
 
V.4.6. Test for tannins 
a. Gelatin test: One mL of extract added with 1% gelatin solution containing 
10% sodium chloride. Formation of white precipitate indicates the presence of 
tannins. 
b. Ferric chloride test: One mL of extract was added with 1mL ferric 
chloride solution. Formation of a dark blue or greenish black colour shows the 
presence of tannins. 
c. Vanillin hydrochloride test: One mL of extract was added with vanillin 
hydrochloride. Formation of a purplish red colour indicate the presence of 
tannins. 
d. Lead acetate test: Little amount of extract was mixed with basic lead 
acetate solution. A white precipitate formation, indicate the presence of 
tannins. 
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e. Ammonia test: A little quantity of extract was treated with potassium ferric 
cyanide and ammonia solution. A deep red colour indicate the presence of 
tannins. 
f. Potassium dichromate test: Extract was treated with 1 mL of Potassium 
dichromate solution (10% w/v). Presence of tannins confirmed by the 
yellowish-brown precipitate. 
V.4.7. Test for steroids 
a. Libermann-Burchard’s test (acetic anhydride test): Two mL of extract 
was added to chloroform solution and 1-2 mL of acetic anhydride and shaken 
well. Appearance of bluish-green colour upon addition of few drops of 
concentrated sulphuric acid along the sides of the test tube, shows the presence 
of steroids.  
b. Salkowsky’s test: Extract was dissolved in chloroform solution and 2 mL 
concentrated sulphuric acid was added. Appearance of chloroform layer in red 
colour indicates the presence of steroids. 
V.4.8. Test for proteins and amino acids 
a. Biuret test: One mL of extract was treated with 4% sodium hydroxide 
solution and few drops of cupric sulphate solution. A purple violet colour 
indicates the presence of proteins. 
b. Ninhydrin test: One mL of extract was treated with 3 drops of 5% 
Ninhydrine solution and heated on a water bath for 10 min. A purplish or 
bluish colour appearance indicates the presence of proteins, peptides or amino 
acid. 
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c. Xanthoproteic test: One mL of concentrated nitric acid was added to 1 mL 
of extract. The mixture was heated and cooled. Sodium hydroxide (40% w/v) 
was added until the mixture become alkaline. Change of yellow colour to 
orange colour indicates the presence of amino acids. 
d. Millon’s test: One mL of extract was treated with millon’s reagent 
(mercuric nitrate in HNO3). White precipitate turns to brick red colour 
indicates the presence of proteins.  
V.4.9. Test for triterpenoids 
Knoller’s test: Two to three pieces of tin metal was dissolved in 2 mL of 
thionyl chloride solution. One mL of extract was added into the test tube and 
warmed. A pink colour indicates the presence of triterpenoids. 
V.4.10. Test for fixed oils and fats 
a. Spot test: Small quantity of extract was pressed between two filter papers. 
An oily stain on the filter paper indicates the presence of fixed oils.  
b. Saponification test: Few drops of 0.5 N alcoholic potassium hydroxide 
was added to the small quantity of extract along with a drop of 
phenolphthalein. The mixture was heated on a water bath for 1 to 2 hours. 
Formation of soap or partial neutralization of alkali indicates the presence of 
fixed oils and fats. 
V.4.11. Test for gums and mucilage
 
Small quantity of extract was dissolved in 10 mL of ethanol and 25 mL of 
absolute alcohol was added slowly with constant stirring. Then the solution 
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was filtered and the precipitate was dried in air. Swelling property of the 
precipitate indicates the presence of carbohydrates. 
V.5. Quantitative estimation of phyto-ingredients presents in L. aspera leaves 
 Quantitative estimation was carried on petroleum ether extract (non-polar) and 
ethanol extract (polar) of L. aspera leaves. The extracts were selected, based on the 
preliminary phytochemical screening results. The total flavonoids, total phenolic 
compounds, total alkaloids and total tannins were estimated with respective 
procedures. 
V.5.1. Estimation of total flavonoid compounds
93
 
 Total flavonoid compounds were estimated by spectrophotometric technique. 
Flavonoids give yellow colour when treated with 1% w/v aluminium chloride reagent 
and this principle was used in the flavonoid estimation. Rutin was used as standard in 
methanol solution (100 mg/mL). Test sample was prepared with methanol to the final 
concentration of 100 mg/mL. One mL of test and standard solutions were taken in a 
separate volumetric flask (10 mL) and 1.0 mL of aluminium chloride reagent was 
added to both the test and standard solutions. Volumes were made up to 10 mL with 
methanol and optical density was measured at 410 nm against blank solution exactly 
at 15 min after the addition of aluminium chloride reagent.  
V.5.2. Estimation of total phenolic compounds
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  Total phenolic content was calculated by calibration curve method using 
Gallic acid (standard), Folin Ciocalteu reagent and 20% sodium carbonate solution. 
Hundred milligrams of crude extract were taken in a micro centrifuge tube. To the 
extract 0.5 mL of distilled water, 1.25 mL of sodium carbonate solution and 0.25 mL 
of Folin-Ciocalteu reagent were added and vortexed. The absorbance of final solution 
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was recorded at 725 nm after 40 minutes. Total phenolic compounds were calculated 
using the Gallic acid equivalent from the calibration curve equation. 
V.5.3. Estimation of total alkaloid compounds 
 The procedure of total alkaloid compounds estimation was adopted from 
Ajanal et al.
95
 Small quantity of extract was dissolved in 2N hydrochloric acid and 
filtered. One mL of this solution was washed with 10 mL chloroform for three times 
in a separation funnel. The pH was adjusted to neutral with addition of 0.1N sodium 
hydroxide solution. To this solution 5 mL of bromocresol green and 5 mL phosphate 
buffer was added, and shaken well. Then the mixture was extracted with 1,2,3 and 4 
mL of chloroform by vigorous shaking. The final concentrate was collected in a 10 
mL volumetric flask and then diluted with chloroform. The absorbance of this 
solution was measured at 470 nm. Atropine was used as standard reference. 
V.5.4. Estimation of total tannins 
The total tannin compounds were estimated by spectrophotometric procedure 
using potassium ferricyanide reagent, ferric chloride reagent and tannic acid 
(standard). Hundred milligrams of crude extract were refluxed with purified water in a 
water bath at 100
0
C±2
0
C for 60 minutes and then cooled. Volume was made up to 100 
mL with purified water.  One mL of potassium ferricyanide and 1.0 mL of ferric 
chloride was added to the standard solution of tannic acid (0.01 mg/mL) for working 
standard and to 1.0 mL of sample solution for working sample in a 10 mL separate 
standard flasks. Volume made up to 10 mL with purified water. Optical density of 
both the standard and test sample was measured at 720 nm exactly after 30 min from 
addition of reagents.  
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V.6. Chromatographic evaluation of L. aspera leaves  
V.6.1. Thin layer chromatography (TLC) studies 
 Thin layer Chromatography (TLC) is an extremely useful technique for 
monitoring reactions. TLC also used to determine the proper solvent system for 
performing separations using column chromatography. A stationary phase and a 
mobile phase are used in TLC.  Usually alumina or silica is used as stationary phase, 
that is highly polar (standard) or non-polar (reverse phase). A mobile phase will be a 
solvent which will be chosen for the elution.  
In non-polar solvents like pentane or hexane, most of the polar compounds 
will not move, while non-polar compounds will travel more distance on the plate. In 
contrast, polar solvent will move non-polar compounds to the solvent front and push 
the polar compounds to the baseline. A good solvent system is one that moves both 
the polar and non-polar compounds from the baseline, but does not put anything on 
the solvent front (Rf value between 0.15 and 0.85) baseline.  
TLC has been used for isolation and identification of compounds from the 
crude extracts. Pre-coated silica gel on aluminum plates (Merck pre-coated Al. Sheets 
- 1.05554) were used as adsorbent for elution. Crude extract was dissolved in high 
performance liquid chromatography (HPLC) grade methanol to the final 
concentration of 10 mg/mL. Based on trial and error method Toluene: Ethyl acetate: 
Acetic acid (55:45:1) was used as mobile phase (eluting agent).  Solvent front run up 
to 80-90% height of the silica plates and spots were observed at 254 nm and 365 nm.  
V.6.2. High performance thin layer chromatography (HPTLC) studies 
 HPTLC chromatography system 
For fingerprinting studies, High Performance Thin Layer Chromatographic 
system equipped with Densitometer 1) Shimadzu flying spot densitometer CS9301 2) 
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Camag TLC Scanner 3 with winCats Planar chromatography manager, Applicator 
CAMAG- Linomat IV and Linomat 5 and saturated developing chamber CAMAG 
Twin trough 20 x 20 cm were used. 
V.6.2.1. Finger printing profile of L. aspera leaves by HPTLC 
For general profiling Toluene: Ethyl acetate: Acetic acid (55: 45: 1) was used 
as a mobile phase. Crude extracts of L. aspera was dissolved in HPLC grade 
Methanol (10 mg/mL) and spotted with sampling machine on a pre-coated Silica gel 
60 F254 (Merck pre-coated Al. Sheets - 1.05554) plates. Solvent front was run up to 9 
cm. Anisaldehyde sulphuric acid was used as spraying agent. 
V.6.2.2. Finger printing profile of flavonoids in L. aspera leaves by HPTLC 
For flavonoids profiling Ethyl acetate: Acetic acid: Formic acid: Water 
(100:11:11:10) was used as a mobile phase. Rutin used as a standard reference. Crude 
extracts of L. aspera were dissolved in HPLC grade Methanol (10 mg/mL) and 
spotted with sampling machine on a pre-coated Silica gel 60 F254 (Merck pre-coated 
Al. Sheets - 1.05554) plates. Solvent front was run up to 9 cm. Aluminium chloride 
(1% w/v) solution was used as spraying agent. 
V.6.2.3. Finger printing profile of steroids in L. aspera leaves by HPTLC  
  For steroids profiling Toluene: Ethyl acetate: Acetic acid (55:45:1) was used 
as solvent mobile phase. Stigmesterol was used as standard reference. Crude extracts 
of L. aspera were dissolved in HPLC grade Methanol (10 mg/mL) and spotted with 
sampling machine on a pre-coated Silica gel 60 F254 (Merck pre-coated Al. Sheets - 
1.05554) plates. Solvent front was run up to 9 cm. Anisaldehyde sulphuric acid 
reagent was used as spraying agent. 
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V.7. Assessment of in vitro antioxidant activity of polar and non-polar solvent 
extracts of L. aspera leaves 
V.7.1. DPPH (Diphenyl-2-picrylhydrazyl) radical scavenging activity 
 DPPH free radical scavenging activity was measured in terms of hydrogen 
donating or radical scavenging ability using stable DPPH radical. This method was 
described by Blois.
96,97
 One mL of 0.1 mM DPPH solution in ethanol was added to 
3.0 mL of extract solution (or standard) and volume was made up with water at 
different concentrations (10 -100 µg/mL). Thirty minutes later absorbance was 
measured at 517 nm. Lower absorbance indicates the higher free radical scavenging 
activity. Capability to scavenge the DPPH radical was calculated using the following 
equation. Mean values were obtained from triplicate of experiment values.  
% inhibition = [(Control OD – Sample OD) / Control OD)] × 100 
 OD – optical density. 
V.7.2. Total antioxidant activity (Phosphomolybdic acid method)  
 Total antioxidant activity of the extract was evaluated by the transformation of 
Mo (VI) to Mo (V) to form phosphomolybdenum complex.
98
 An aliquot of 0.2 mL 
extract solution (10-100 µg/mL) was combined in a vial with 2.0 mL of reagent 
solution (0.6 M sulphuric acid, 28 mM sodium phosphate and 4 mM ammonium 
molybdate). The vials were capped and incubated in a water bath at 95ºC for 30 min. 
Samples were cooled to room temperature and the absorbance was measured at 695 
nm against blank solution. Total antioxidant activity was expressed relative to that of 
ascorbic acid. 
V.7.3. Nitric oxide radical scavenging activity 
 Nitric oxide radical scavenging activity procedure was adopted from Garratt 
DC et al.
99
 report and Rutin was used as standard. Nitric oxide was generated from 
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sodium nitroprusside in aqueous solution at physiological pH, which interacts with 
oxygen to produce nitric ions, which may be determined by the Griess Ilosvay 
reaction. Two mL of 10 mM sodium nitro prusside and 0.5 mL of phosphate buffer 
saline (pH 7.4) was mixed with 0.5 mL of sample at different concentrations (10-100 
µg/mL) and the mixture incubated at 25ºC for 2.5 hours. Incubated mixture (1.5 mL) 
was added to 1.5 mL of griess reagent (1% sulphanilamide, 2% o-phosphoric acid, 
0.1% napthyl ethylene diamine di hydrochloride) and again incubated at room 
temperature for 5 min. The absorbance of the mixture was read at 546 nm. 
Percentage inhibition (%) = [(Abscont - Abstest) / Abscont] x 100 
V.7.4. ABTS (2, 2,-azinobis (3-ethylbenzoline-6-sulfonic acid) radical scavenging   
activity  
  Scavenging activity of extract was tested by using ABTS
+
 assay and quercetin 
was used as standard. This method was described with a slight modification by         
Re et al.
100 
The ABTS
+
 radical solution was prepared by mixing 14 mM ABTS stock 
solution with 4 mM ammonium per sulphate and incubating for 16 hr at room 
temperature in the dark until the reaction was stable. Absorbance of ABTS
+
 solution 
was equilibrated to 0.70±0.02 by diluting with ethanol at room temperature. To 1.0 
mL of ABTS
+
 solution various concentrations of test samples (10-100 µg/mL) was 
added. Six minutes later the absorbance was measured at 734 nm. Percentage 
inhibition of absorbance was calculated by using the following equation.  
Percentage Inhibition (I %) = {(Abscontrol- Abssample) /Abscontrol)} x 100 
V.8. Assessment of in vitro anti-diabetic activity of polar and non-polar solvent    
extracts of L. aspera leaves in C2C12 cell line 
 Skeletal muscle is the primary responsible site for postprandial glucose use 
and it is the most abundant tissue in the whole body. Defects in insulin stimulated 
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skeletal muscle, glucose uptake are common pathological states in type-2 DM.
101
 The 
aim of this in vitro anti-diabetic study was to elucidate the anti-diabetic activity of 
ethanol (polar) and petroleum ether (non-polar) extracts with cell viability by MTT 
assay and in vitro glucose uptake assay using C2C12 cell lines before the animal 
experiments.  
V.8.1. Determination of cell viability by MTT assay 
Chemicals: MTT {3-(4,5–dimethyl thiazol–2–yl)–5–diphenyl tetrazolium 
bromide}, fetal bovine serum (FBS), phosphate buffered saline (PBS), bovine serum 
albumin (BSA), D-glucose, dulbecco’s modified eagle’s medium (DMEM), 
metformin, trypsin (Sigma Aldrich Co., St Louis, USA), EDTA, antibiotics, insulin, 
dimethyl sulfoxide (DMSO), NaOH and propanol. 
Cell lines and culture medium: Stock cells of C2C12 (rat skeletal muscle, 
ATCC, USA) were cultured in DMEM, supplemented with 10% inactivated FBS, 
penicillin (100 IU/mL), streptomycin (100 g/mL) and amphotericin B (5 g/mL) in a 
humidified atmosphere of 5% carbon dioxide at 37C until confluent. The cells were 
dissociated with TPVG solution (0.2% trypsin, 0.02% EDTA, 0.05% glucose in PBS). 
The stock cultures were grown in 25 cm
2
 culture flasks and all experiments were 
carried out in 96 microtitre plates (Tarsons India Pvt. Ltd., Kolkata, India).  
Test solution: For in vitro anti-diabetic studies, test substance dissolved in 
DMEM supplemented with 2% inactivated fetal bovine serum to obtain a stock 
solution of 1.0 mg/mL. This solution was sterilized by filtration and two-fold serial 
dilutions are prepared to carryout cytotoxic studies. 
Procedure: The cytotoxic capacity of ethanol extract and petroleum ether 
extract was determined by MTT assay. This method was adopted from the procedure 
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explained by Francis Denizot and Rita Lang.
102
 Monolayer cell culture was 
trypsinized and cell count was adjusted to 1.0x10
5 
cells/mL using DMEM containing 
10% of FVS. To each well, 0.1 mL of diluted cell suspension was added. Supernatant 
was flicked off after 24-h and monolayer was washed once with medium.  Different 
concentrations of extracts (100 µL) were added on to the partial monolayer in 
microtitre plates. The plates were incubated at 37
o 
C for 3 days in 5% carbon dioxide 
atmosphere. Microscopic examination was carried out and observations noted at 24-h 
interval. Te drug solutions in the wells were discarded after 24-h and 50 l of MTT in 
phosphate buffered saline was added to each well and gently shaken. This mixture 
was again incubated for 3-h at 37
o
C in 5% carbon dioxide atmosphere. The 
supernatant was removed and 100 L of propanol was added to the plates, gently 
shaken to solubilize the formed formazan. The absorbance was measured using a 
micro plate reader at a wavelength of 540 nm. The percentage growth inhibition was 
calculated using the following formula and concentration of test drug needed to 
inhibit cell growth by 50% (CTC50) values is generated from the dose-response curves 
for each cell line. 
V.8.2. In vitro glucose uptake assay 
 Glucose uptake activity of ethanol extract and petroleum ether extract was 
measured in differentiated C2C12 cells. This method was explained by              
Hisako et al.
103
 The 24-h cell culture with 70-80% confluency in 40 mm petri-dish 
plates were allowed to differentiate by maintaining in DMEM with 2% FBS for 4-6 
days. The differentiated cells were serum starved over a night and at the time of 
experiment cells were washed with HEPES buffered Krebs Ringer Phosphate solution 
(KRP buffer). Mixture is incubated with KRP buffer with 0.1% BSA for 30 min at 
37
0
C. Cells were treated with different non-toxic concentrations of standard drug and 
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extracts for 30 min along with negative controls at 37
0
C. D-glucose solution (20µL) 
was added simultaneously to each well and incubated at 37
0
C for 30 min. After 
incubation, the uptake of the glucose was terminated by aspiration of solutions from 
wells and washed thrice with ice-cold KRP buffer solution. Cells were lysed with 
0.1M NaOH solution and an aliquot of cell lysates were used to measure the cell-
associated glucose. The glucose levels in cell lysates were measured using glucose 
assay kit (ERBA). Two independent experimental values in duplicates were taken to 
determine the percentage enhancement of glucose uptake over controls.  
V.9. Animal experimental studies 
V.9.1. Ethical committee clearance 
 This study was approved by an Institutional Animal Ethics Committee (IAEC) 
of CPCSEA (Committee for the Purpose of Control and Supervision of Experiments 
on Animals) from the KMCH College of Pharmacy, Coimbatore, Tamil Nadu. 
(KMCRET/Ph.D/09/2015-16, dated 22.08.2015; Appendix-2). 
V.9.2. Acute oral toxicity study 
 Acute oral toxicity study was carried out according to the OECD 423 
guidelines.
104
 Eight to twelve weeks old female albino mice were used for the acute 
toxicity studies based on the availability of animals and recommendation of rodent 
species for oral studies. Selected animals were randomly allotted into four groups 
containing minimum 3 animals in each group. L. aspera leaf extracts were orally 
administered to each group at the dose of 5 mg/kg, 50 mg/kg, 300 mg/kg, and 2000 
mg/kg respectively and observed for a period of 14 days for any signs of toxicity. 
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V.9.3. Induction of hyperlipidemia  
 Hyperlipidemia was induced by high-fat diet method.  The animals were fed 
with high fat cocktail diet which consisted of cholesterol (2%), cholic acid (1%), 
dalda (20%) and coconut oil (6%) for 4 weeks.
105,106
 At the end of 4 weeks, blood 
sample was collected by retro-orbital plexus of rats under ether anaesthesia and total 
cholesterol was estimated by standard diagnostic test kit to confirm the induction of 
hyperlipidemia.   
V.9.4. Induction of type 2 diabetes mellitus 
 At the end of 4 weeks, the hyperlipidemic rats were kept overnight fasting and 
the initial fasting blood glucose levels were checked from tip of rat tail vein. Non-
insulin dependent diabetes mellitus (type 2 DM) was induced in overnight fasted rats 
by administering a single intraperitoneal injection of Streptozotocin (STZ; 60 mg/kg) 
and 120 mg/kg of Nicotinamide at 15 min interval. Hyperglycemia was confirmed by 
measuring elevated blood glucose levels after 72 hr. The animals with blood glucose 
levels more than 250 mg/dL were considered as diabetic rats.
107
 
 Through the above said method, diabetes and hyperlipidemia were induced in 
the same animals.
108-110
 A calculated dose of petroleum ether extract and ethanol 
extract of L. aspera was administered from the first day of week-5 and animals were 
allowed for free access to food and water till the completion of study (till week-8). 
Glibenclamide 0.5 mg/kg and atorvastation 10 mg/kg was used as standard drug for 
the treatment.
 
V.9.5. Experimental design (grouping of animals) 
 Based on acute oral toxicity study, the dose of ethanol extract of L. aspera 
leaves (EELA) and petroleum ether extract of L. aspera leaves (PELA) extracts were 
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fixed at 250 mg/kg as low dose and 500 mg/kg as high dose for the treatment purpose.  
Animals were randomly allotted in to 7 groups which consisting of with 6 animals in 
each group.  After the grouping EELA, PELA and standard drugs were administered 
to the respective group of animals.  
Group 1: Normal control rats. No treatment was given.  
Group 2: Type 2 DM and hyperlipidemia-induced rats. Administered with 1.0 mL of 
water for injection. (Disease control). 
Group 3: Type 2 DM and hyperlipidemia induced rats. Administered with 
glibenclamide (0.5 mg/kg/day) and atorvastatin (10 mg/kg) orally in 
aqueous solution for 4 weeks. (Standard treatment group).        
Group 4: Type 2 DM and hyperlipidemia-induced rats, orally administered with     
EELA (250 mg/kg/day) in aqueous solution for 4 weeks. 
Group 5: Type 2 DM and hyperlipidemia-induced rats, orally administered with   
EELA (500 mg/kg/day) in aqueous solution for 4 weeks. 
Group 6: Type 2 DM and hyperlipidemia-induced rats, orally administered with    
PELA (250 mg/kg/day) in aqueous solution for 4 weeks. 
Group 7: Type 2 DM and hyperlipidemia-induced rats, administered with PELA (500   
mg/kg/day) in aqueous solution for 4 weeks. 
V.9.6. Determination of biochemical parameters 
 All the biochemical and hematological parameters were measured at the 
beginning of study (week 0), after disease induction / before treatment (week 4) and 
after treatment/end of study (week 8). Blood samples were collected and stored at        
-20
0
C freezer for further analysis. Body weight gain was recorded on weekly basis 
until study completion. Respective procedures from the literatures were used for the 
determinations/estimations. 
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V.9.6.1. Determination of blood glucose 
    Blood samples were collected from tip of the tail vein and glucose levels 
were measured by using a glucometer (Accu-chek, Roche Diagnostics, USA) with 
glucose oxidase-peroxidase reactive strips. 
V.9.6.2. Determination of serum total cholesterol  
The serum total cholesterol levels were determined after the enzymatic 
hydrolysis and oxidation of the sample as described by Stein.
111
 In brief, 1000 µL of 
the reagent was added to each of the sample and standard solutions. These mixtures 
were incubated at 20-25ºC for 10 min. The absorbance of the sample and standard 
was measured against the blank reagent within 30 min after incubation at 546 nm. The 
value of total cholesterol present in serum was expressed as mg/dL (mg%). 
Total Cholesterol = Sample / Standard × 196.86 
V.9.6.3. Determination of serum triglycerides 
  The serum triglycerides level was measured after the enzymatic hydrolysis of 
sample with lipases as described by Tietz.
112
 Briefly, the reagent (1000 µL) was added 
to each of the sample and standard solutions. The mixtures were incubated at 20-25ºC 
for 10 min. The absorbance of the sample and standard was measured against the 
blank within 30 min after incubation at 546 nm. The amount of triglycerides present 
in serum was expressed as mg/dL. 
TGL concentration = Sample / Standard × 194.0 
V.9.6.4. Determination of serum HDL-cholesterol 
Estimation of serum HDL-cholesterol was measured by the method described 
by Warnick and Alber.
113
 LDL-cholesterol, VLDL-cholesterol and chylomicron 
fractions in the sample were precipitated by the addition of phosphotungstic acid in 
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the presence of magnesium ions. At room temperature, the mixture was allowed to 
stand for 10 min and then centrifuged at 4000 rpm for 10 min. The supernatant was 
represented the HDL-cholesterol fraction. The cholesterol concentration in the HDL 
fraction, which remained in the supernatant was determined. The value of HDL-
cholesterol was expressed in the unit of mg/dL. 
V.9.6.5. Determination of serum LDL-cholesterol  
The serum LDL-cholesterol was calculated by using the following equation, as 
it was explained by Friedewald et al.
114
 using the equation below. The value was 
expressed in the unit of mg/dL. 
LDL-C = TGL/5 - HDL-C 
V.9.6.6. Determination of urea, uric acid and creatinine 
A simple spectrophotometric technique was used to determine the urea levels 
in blood. This method was explained by With TK et al.
115
 The reagents were mixed 
with the animal blood samples in a separate standard flask. The mixture was shaken 
well and filtered. Spectrophotometric reading was taken in a double beam UV-
spectrophotometer using clear filtrate at 420 nm against a blank solution.  
The uric acid level in serum was determined by fluorometric determination by 
its reaction with uricase enzyme. This method was described by Galban J et al.
116
 The 
procedure is based on enzymatic reaction of uricase and uric acid which produces the 
changes in fluorescence at 287 nm.  emission was measured at 330 nm.  
Serum creatinine levels were measured by the spectrophotometric method 
described by Krishnegowda A et al.
117
 Analytical grade reagents were used for the 
assay. All regents were prepared freshly for the procedure. Blood samples were mixed 
with 3 mL of reagent containing Metol (1.93 mM), copper (68.6 μM) and 1 mM 
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acetic acid/sodium acetate buffer (pH 5.4). The reaction mixtures were allowed to 
stand at room temperature for 30 min. Absorbance was recorded at 530 nm. 
V.9.6.7. Determination of SGPT and SGOT 
SGPT and SGOT were determined by the method explained by Begum.
118
 
SGPT substrate (0.5ml) was used for SGOT analysis. Substrates were added in the 
two separate test tubes and incubated in a water bath at 27 °C for about 5 min. Blood 
samples were added to the test tube and again incubated for 30 min at 37°C. The 
reagent (0.5 mL DNPH) was added to both the test and standard tubes, and mixed 
well by vigorous shaking. Then the mixture was incubated at room temperature for 20 
min. Sodium hydroxide (0.4N, 5mL) was added to the test tubes and the mixture was 
incubated for 10 min. The optical density was measured using at 540 nm using green 
filter. 
V.10. Antidepressant studies 
 To assess the diabetes-induced or associated depressive status, animals were 
tested for anti-depressant models. Tail suspension method and forced swim tests were 
performed at week-4 (before the treatment) and week-8 (after the treatment). 
V.10.1. Tail suspension test 
 The total duration of immobility, induced by tail suspension was measured by 
the standard method.
119
 Rats were suspended on the edge of a table about 50 cm from 
the floor by the adhesive tape placed approximately 1 cm from the tip of the tail. The 
total duration of immobility was recorded for six minutes. Animals were considered 
to be immobile when they hung passively and completely motionless. 
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V.10.2. Forced-swim test 
 This test was proposed as a model to test antidepressant activity by         
Porsolt et al.
120
 Animals were forced to swim individually in glass jar (25 x 12 x 25 
cm) containing fresh water up to 15 cm height and maintained at 25
0
C. Two minutes 
later each animal assumed a typical immobile posture after vigorous activity. Animals 
were considered to be immobile when it remained floating in the water without 
struggling, making only minimum movements of its limbs, necessary to keep its head 
above the water. The total duration of immobility was recorded for next 4 min. Each 
animal was used only once. 
V.11. Determination of antioxidant enzymes and lipid peroxidation (in vivo   
antioxidant enzymes studies)  
V.11.1. Preparation of tissue homogenate 
At the end of the experimental studies (after the treatment with EELA and 
PELA), animals were sacrificed by euthanasia method. Organs (Liver and Kidney) 
were isolated from one animal in each group and tested separately for the in vivo 
antioxidant enzymatic activities.   
Isolated organs (kidney and liver) were washed with normal saline and stored 
for in vivo antioxidant studies. The organs were homogenized separately with motor 
driven Teflon coated homogenizer in 0.1 M Tris-HCl buffer (pH 7.4) to get 10% 
homogenate. The homogenate was centrifuged at 10000 rpm for 10 min at 5˚C. The 
supernatant was collected and used for in vivo studies. The antioxidant studies 
included, super oxide dismutase, catalase, glutathione peroxidase, reduced glutathione 
and lipid peroxidation. 
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V.11.2. Estimation of superoxide dismutase (SOD) 
 Superoxide dismutase scavenging activity was measured by a modified 
method described by Kakkar P et al.
121
 Kidney and liver homogenates (0.5 mL) were 
diluted with distilled water (0.5 mL) and added with 0.25 mL of ethanol and 0.15 mL 
of chloroform. The mixture was centrifuged at 2000 rpm for a minute and supernatant 
was removed. Buffer (1.5 mL) and epinephrine (0.4 mL) was added to the 0.5 mL of 
tissue homogenates and optical density was read at 480 nm in double beam UV 
spectrophotometer. Activity of SOD was expressed as unit/min/mg of protein. 
V.11.3. Estimation of catalase (CAT) 
 All major body organs of animals contain catalase and it is more concentrated 
in liver.  Hydrogen peroxide is generated by β-oxidation of fatty acids by influence of 
flavoprotein dehydrogenase. The activity of catalase was determined by colourimetric 
assay described by Sinha AK.
122
 Tissue homogenates (0.1 mL; of kidney and liver) 
was added with phosphate buffer (1.0 mL) and hydrogen peroxide. Reaction was 
stopped by adding 0.2 mL of dichromate acetic acid reagent. Hydrogen peroxide 
standard was used and the tubes were heated in water bath for 10 min. Optical density 
was read by using UV double beam spectrophotometer at 570 nm after the appearance 
of green colour. Activity of catalase was expressed as µmol of hydrogen peroxide 
consumed/min/mg protein. 
V.11.4. Estimation of glutathione peroxidase (GPx) 
 Glutathione was measured by its reaction with DTNB to give a compound that 
absorbs at 412 nm. The activity of glutathione peroxidase was measured according to 
the method of Rotruck et al.
123
 Mixture of tissue homogenate (0.1 mL), EDTA, 
reduced glutathione, hydrogen peroxide, sodium azide and buffer (0.4 mL) were 
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incubated at 37°C for 10 min. Addition of 0.5 mL trichloro acetic acid arrested the 
reaction and tubes were centrifuged. To 0.5 mL of supernatant liquid, sodium 
hydrogen phosphate (3 mL) and DTNB (1 mL) were added and optical read at 412 nm 
immediately after colour formation. Activity of glutathione peroxidase is expressed as 
µmoles of   glutathione oxidized/min/mg protein. 
V.11.5. Estimation of reduced glutathione (GSH)      
    Ellman’s reagent (DTNB; 5,5’-dithiobis (2-nitrobenzoic acid), was used for 
the detection of thiol compounds. Glutathione and DTNB reaction generates 2-nitro-
5-thiobenzoic acid and glutathione disulfide (GSSG). Estimation of reduced 
glutathione was carried out by using Ellman’s procedure.124 Tissue homogenate (250 
L) was mixed with 1.0 mL of 5% TCA in a 2 mL eppendorf tube and centrifuged at 
3000 rpm for 10 min at room temperature. From the above mixture, 250 L of 
supernatant was added to 1.5 mL of 0.2 M phosphate buffer and 250 L of 0.6 mM of 
Ellman’s reagent. The absorbance of mixture was measured at 412 nm within 10 min. 
A standard graph was plotted using glutathione reduced solution (1.0 mg/mL) and 
GSH content present in the tissue homogenates was calculated by interpolation. 
Amount of glutathione expressed as g/mg of protein. 
V.11.6. Estimation of lipid peroxidation (LPO) 
 Malondialdehyde (MDA) and other thiobarbituric acid reactive substances 
(TBARS) were estimated by thiobarbituric acid reaction in acidic condition to 
generate a pink coloured chromophore. Lipid peroxidation was determined by 
thiobarbituric reaction method described by Ohkawa et al.
125
 One mL of liver and 
kidney tissue homogenate was mixed with 4% sodium dodecyl sulfate (0.2 mL; 4%), 
20% acetic acid (1.5 mL) in 0.27 M hydrochloric acid (pH 3.5) and 0.8% 
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thiobarbituric acid (15 mL). The mixture was heated in a hot water bath at 85˚C for 
one hour. The intensity of the pink colour developed was read at 532 nm against blank 
following centrifugation at 1200 g for 10 min. The concentration was expressed as 
nmol of MDA/mg protein. 
V.12. Histopathological examination 
The extent of damage to the pancreatic cells, gross anatomy of pancreas and 
the effect of the L. aspera leaf extracts were studied through histopathology 
examinations. Small pieces of pancreatic tissues were collected from each group in 
10% formaldehyde solution for histopathological study. The tissue specimens of 
pancreas were processed and embedded in paraffin wax block about 4-6 μm in 
thickness and photographs were obtained after staining.  
V.13. Statistical analysis 
 Statistical analyses were performed using SPSS version 15.0 for Windows 
(SPSS Inc., Chicago, IL, USA) and Graph Pad Prism version 6.0 for Windows 
(GraphPad Software, La Jolla California USA).  The statistical analysis, calculations, 
and graphic interfaces were performed on a personnel computer. Continuous variables 
are expressed as mean±SD and mean±SE appropriately.  Categorical variable are 
presented as numbers or percentages. The significance of differences between the 
groups was assessed using one-way analysis of variance (ANOVA) followed by 
Dunnet’s multiple comparisons test was performed. P values less than 0.05 (95% 
confidence interval) were considered as significant. 
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VI. RESULTS (Observations) 
VI. 1. Qualitative screening of phytochemicals 
 The preliminary phytochemical investigations were carried out on five 
different solvent extracts with increasing in polarity. The solvents included petroleum 
ether, ethyl acetate, chloroform, ethanol and isopropyl alcohol extracts of L. aspera 
leaves. The results showed the presence of flavonoids, alkaloids, glycosides, 
carbohydrates and less extent of steroids, terpenoids, tannins, phenolic compounds in 
L. aspera leaves.  Petroleum ether extract (non-polar) and ethanol extract (polar) 
showed the presence of maximum number of compounds. The complete detail of 
phytochemical screening is presented in Table 8. The results confirm that L. aspera 
leaves are good source of flavonoids, alkaloids, carbohydrates and glycosides, etc. 
Table 8: Preliminary phytochemical screening of L. aspera leaves 
Phytochemicals 
Petroleum 
ether 
extract 
Ethyl 
Acetate 
extract 
Chloroform 
extract 
Isopropyl 
alcohol 
extract 
Ethanol 
extract 
Alkaloids ++ + + ++ ++ 
Flavonoids ++ + + ++ ++ 
Carbohydrates ++ ++ + + ++ 
Tannins + + + + + 
Triterpenoids + + + + - 
Glycosides + + + + ++ 
Steroids + - - - + 
Phenolic 
compounds 
+ + - + + 
Fixed oil & Fat + - - - - 
Proteins - + + + + 
Saponins - + - - + 
++ Strong positive; + Positive; – Negative/Absent. 
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VI. 2. Quantitative estimation of phyto-ingredients presents in L. aspera leaves 
 The quantitative estimation of phyto-ingredients includes, total phenolic 
compounds, total alkaloid compounds, total flavonoid compounds and total tannins 
were measured in petroleum ether, ethyl acetate, chloroform, ethanol and isopropyl 
alcohol extracts of L. aspera leaves. These compounds are directly contributing to 
antioxidant activity.  
The amount of total flavonoids, total phenolic compounds, total tannins and total 
alkaloids present in petroleum ether (non-polar solvent) extract of L. aspera leaf was 
found to be 13.22, 12.96, 0.17 and 4.05 g per 100 g of crude extracts respectively. The 
ethanol extract (polar solvent) showed 15.97, 12.26, 0.79 and 2.15 g per100 g of dried 
crude extract respectively. Quantitative estimations confirmed that total flavonoid 
compounds and total phenolic compounds are the major content present in the leaves 
of L. aspera compared to alkaloids and tannins. The complete details of amount of 
phyto-ingredients present in the L. aspera leaf are summarized in table 9. 
Table 9: Amount of phyto-ingredients presents in L. aspera leaves 
Phytochemicals 
Petroleum 
ether 
extract 
Ethyl 
Acetate 
extract 
Chloroform 
extract 
Isopropyl 
alcohol 
extract 
Ethanol 
extract 
Total flavonoid 
compounds 
13.22 14.90 13.22 13.39 15.97 
Total phenolic 
compounds 
12.96 9.25 14.01 10.65 12.26 
Total alkaloid 
compounds 
4.05 4.20 13.95 7.16 2.15 
Total tannins 0.17 0.53 0.83 0.55 0.79 
* all values are expressed in grams per 100 grams. 
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VI. 3. In vitro antioxidant studies 
VI. 3.1. DPPH radical scavenging activity 
 Petroleum ether, ethanol and isopropyl alcohol extracts of L. aspera leaves 
exhibited a significant dose dependent DPPH scavenging activity. Among the 
solvents used in the study, petroleum ether extract had shown 66%, 68%, 69%, 70%, 
71% and 72% of scavenging activity at 10, 20, 40, 60, 80 and 100 μg/mL 
concentrations respectively. Whereas ethanol extract had shown 64%, 67%, 71%, 
76%, 81% and 87% with the same concentrations. On the other hand, ascorbic acid 
standard showed 21%, 33%, 34%, 46%, 58% and 74% of activity with the same 
concentrations. Percentage of scavenging activity or percentage inhibition was 
calculated by linear regression method. The IC50 values of ascorbic acid, petroleum 
ether extract, ethanol extract and isopropyl alcohol extract was found to be 27.05 
μg/mL, 18.96 μg/mL, 19.90 μg/mL and 24.74 μg/mL respectively. The DPPH 
scavenging activity of various solvent extracts of L. aspera leaves are presented in 
table 10 and figure 4. 
Table 10: Optical density and IC50 values of DPPH scavenging activity of L. 
aspera   leaves 
Sl.No 
Concentration 
(mcg/mL) 
Ascorbic 
acid 
(Standard) 
IPA ETOH CHCl3 PET EA 
1 10 0.09 0.93 0.87 0.87 0.55 0.72 
2 20 0.12 0.82 0.81 0.85 0.66 0.71 
3 40 0.15 0.72 0.76 0.81 0.70 0.70 
4 60 0.19 0.64 0.71 0.74 0.67 0.69 
5 80 0.20 0.62 0.67 0.71 0.66 0.68 
6 100 0.21 0.46 0.64 0.68 0.37 0.66 
 Ic 50 values 27.05 24.74 19.90 86.79 18.96 74.14 
IPA-isopropyl alcohol; ETOH-ethanol; ChCl3-chloroform; EA-ethyl acetate; PET-
petroleum ether. 
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Figure 4: DPPH radical scavenging activity of various solvent extracts of              
L. aspera leaves  
 
VI. 3.2. Total antioxidant activity 
 The total antioxidant capacity of various solvent extracts of L. aspera leaves 
were calculated using the standard curve of ascorbic acid (y = 0.029+0.021; R2 = 
0.813) and expressed as number of equivalent of ascorbic acid per gram of extract. 
The IC50 values of total antioxidant capacity of ascorbic acid, petroleum ether extract, 
ethanol extract, isopropyl alcohol extract, chloroform extract and ethyl acetate extract 
was found to be 17.23μg/mL, 17.22 μg/mL, 21.58 μg/mL, 10.40 μg/mL, 37.78 μg/mL 
and 23.61 μg/mL respectively.  
Amongst, petroleum ether, ethanol and isopropyl alcohol exhibited significant 
dose dependent antioxidant activity. The total antioxidant activity of various solvent 
extracts L. aspera leaves are presented in table 11 and figure 5.  
  
Results 
61 
 
Table 11: Optical density and IC50 values of total antioxidant activity of L. aspera     
leaves 
Sl.No 
Concentration 
(mcg/mL) 
Ascorbic 
acid 
(Standard) 
IPA ETOH CHCl3 EA PET 
1 10 0.124 0.142 0.426 0.112 0.109 0.236 
2 20 0.132 0.208 0.801 0.284 0.526 0.498 
3 40 0.142 0.228 0.878 0.449 0.816 0.791 
4 60 0.156 0.252 0.973 0.502 0.958 0.876 
5 80 0.181 0.285 0.998 0.638 1.136 0.942 
6 100 0.225 0.342 1.042 0.815 1.143 1.03 
 Ic 50 values 17.23 10.40 21.58 37.68 23.61 17.23 
IPA-isopropyl alcohol; ETOH-ethanol; ChCl3-chloroform; EA-ethyl acetate; PET-
petroleum ether. 
 
Figure 5: Total antioxidant activity of various solvent extracts of L. aspera leaves 
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VI. 3.3 Nitric oxide scavenging activity 
 Nitric oxide is a free radical and over production of nitric oxide radicals 
contributes to some inflammatory diseases. Ethanol extract and petroleum ether 
extract were exhibited the higher nitric oxide scavenging activity compared to 
chloroform, ethyl acetate and isopropyl alcohol extracts. The IC50 values of total nitric 
acid scavenging activity of petroleum ether extract, ethanol extract, isopropyl alcohol 
extract, chloroform extract and ethyl acetate extract was found to be 11.87 μg/mL, 
13.47 μg/mL, 24.26 μg/mL, 13.58 μg/mL, and 20.75 μg/mL respectively. Out of 
which ethanol and petroleum ether extracts showed higher nitric acid scavenging 
activity compared to other solvent extracts. The nitric oxide scavenging activity of 
various solvent extracts L. aspera leaves are presented in table 12 and figure 6.  
Table 12: Optical density and IC50 values of nitric oxide scavenging activity of      
L. aspera leaves 
Sl. No 
Concentration 
(μg/mL) 
EA PET CHCl3 IPA ETOH 
1 10 2.34 2.48 2.42 2.45 2.42 
2 20 2.18 2.43 2.36 2.43 2.39 
3 40 1.89 2.36 2.33 2.35 2.38 
4 60 1.64 2.28 2.20 2.33 2.35 
5 80 1.40 2.20 2.14 2.20 2.22 
6 100 1.13 2.11 2.12 2.14 2.34 
 Ic 50 values 20.75 11.87 13.58 24.26 13.47 
IPA-isopropyl alcohol; ETOH-ethanol; ChCl3-chloroform; EA-ethyl acetate; PET-
petroleum ether. 
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Figure 6: Nitric oxide scavenging activity of various solvent extracts of L. aspera   
leaves 
 
VI. 3.4. ABTS assay 
 The scavenging activity of 2,2,-azinobis (3-ethylbenzoline-6-sulfonic acid 
(ABTS+) assay was measured with the comparison of quercetin standard reference. 
Among the extracts, petroleum ether, ethanol and chloroform extracts were exhibited 
better inhibition compared to quercetin standard. Petroleum ether extract exhibited 
33%, 38%, 53%, 64%, 71% and 72% of scavenging activity and ethanol extract had 
shown 3%, 8%, 15%, 23%, 34% and 77% at 10, 20, 40, 60, 80 and 100 μg/mL 
concentrations respectively. The IC50 values of quercetin petroleum ether, chloroform 
and ethanol were found to be 16.66 µg/mL, 16.0 µg/mL, 17.08 µg/mL and 11.6 
µg/mL respectively. The ABTS++ assay of various solvent extracts L. aspera leaves 
are presented in table 13 and figure 7.  
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Table 13: Optical density and IC50 values of ABTS
++ assay of L. aspera leaves 
Sl. No 
Concentration 
(mcg/mL) 
Quercetin 
(Standard) 
IPA ETOH CHCl3 EA PET 
1 10 0.298 0.91 1.124 0.49 0.626 0.591 
2 20 0.256 0.856 0.826 0.25 0.612 0.593 
3 40 0.236 0.715 0.758 0.47 0.586 0.398 
4 60 0.209 0.639 0.735 0.55 0.356 0.296 
5 80 0.176 0.425 0.624 0.65 0.291 0.223 
6 100 0.128 0.318 0.215 0.68 0.21 0.214 
 Ic 50 values 16.16 61.76 11.60 17.08 52.93 16.00 
IPA-isopropyl alcohol; ETOH-ethanol; ChCl3-chloroform; EA-ethyl acetate; PET-
petroleum ether. 
 
Figure 7: ABTS++ assay of various solvent extracts of L. aspera leaves 
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Table 14: Summary of free radical scavenging and iron chelating activity (IC50 
values) of various solvent extracts of L. aspera leaves (p value ≤ 0.05) 
Antioxidant activity 
Crude extract of L. aspera leaves IC50 values (µg/mL) 
PET EA ETOH IPA ChCl3 Std
# 
DPPH scavenging activity 18.96* 74.14 19.90* 24.74 86.79 27.05 
Total antioxidant activity 17.22* 23.61 21.58 10.40* 37.68 17.23 
ABTS assay 16.00* 52.93 11.60* 61.76 17.08 16.16 
Nitric oxide scavenging 
activity 
11.87* 20.75 13.47* 24.26 13.58* - 
PET-petroleum ether / EA-ethyl acetate / ETOH-ethanol / IPA-isopropyl alcohol / 
ChCl3-chloroform / Std-standard used.  
$all values are expressed in grams per 100 grams. Values are obtained from average of 
3 determinations.  
*significant antioxidant activity (p value ≤ 0.05). 
# Ascorbic acid used as standard for DPPH and total antioxidant activity. Quercetin 
used as standard for ABTS assay. 
 
VI. 4. TLC and HPTLC studies 
VI. 4.1. TLC and HPTLC general profiles of L. aspera leaves 
 TLC is the basic method widely used as the primary isolation technique by 
researchers. HPTLC is the enhanced form of TLC procedure, which can overcome the 
common problems (droplet size and position) faced in TLC.  HPTLC profiles of 
various solvent extracts of L. aspera leaves were generated to ascertain the total 
number of different chemical moieties.  
  The general TLC profile and HPTLC finger print chromatogram of various 
solvents extracts of L. aspera leaves are presented in figures 8 to 17. The profiles 
showed number of eluted compounds at 254 nm, 366 nm and 550 nm.  
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Figure 8: TLC general profile of petroleum ether extract of L. aspera leaves 
 
 
Figure 9: HPTLC chromatogram shows general profile of petroleum ether 
extract   of L. aspera leaves 
 
 
 
Mobile phase: Toluene: Ethyl acetate: Acetic acid (55: 45: 1) 
Spray Reagent: Anisaldehyde sulphuric acid 
Sample concentration: 10 mg / 1.0 mL of HPLC grade Methanol 
Adsorbent: Silica gel 60 F254 (Merck pre-coated Al. Sheets - 1.05554) 
Solvent front run: Up to 9 cm  
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Figure 10: TLC general profile of ethanol extract of L. aspera leaves 
 
Figure 11: HPTLC chromatogram shows general profile of ethanol extract of         
L. aspera leaves 
 
 
 
Mobile phase: Toluene: Ethyl acetate: Acetic acid (55: 45: 1) 
Spray Reagent: Anisaldehyde sulphuric acid 
Sample concentration: 10 mg / 1.0 mL of HPLC grade Methanol 
Adsorbent: Silica gel 60 F254 (Merck pre-coated Al. Sheets - 1.05554) 
Solvent front run: Up to 9 cm  
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Figure 12: TLC general profile ethyl acetate extract of L. aspera leaves 
 
Figure 13: HPTLC chromatogram shows general profile of ethyl acetate extract 
of L. aspera leaves 
 
 
 
Mobile phase: Toluene: Ethyl acetate: Acetic acid (55: 45: 1) 
Spray Reagent: Anisaldehyde sulphuric acid 
Sample concentration: 10 mg / 1.0 mL of HPLC grade Methanol 
Adsorbent: Silica gel 60 F254 (Merck pre-coated Al. Sheets - 1.05554) 
Solvent front run: Up to 9 cm  
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Figure 14: TLC general profile chloroform extract of L. aspera leaves 
 
Figure 15: HPTLC chromatogram shows general profile of chloroform extract of         
L. aspera leaves 
 
 
 
Mobile phase: Toluene: Ethyl acetate: Acetic acid (55: 45: 1) 
Spray Reagent: Anisaldehyde sulphuric acid 
Sample concentration: 10 mg / 1.0 mL of HPLC grade Methanol 
Adsorbent: Silica gel 60 F254 (Merck pre-coated Al. Sheets - 1.05554) 
Solvent front run: Up to 9 cm  
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Figure 16: TLC general profile isopropyl alcohol extract of L. aspera leaves 
 
 
Figure 17: HPTLC chromatogram shows general profile of isopropyl alcohol 
extract of L. aspera leaves 
 
 
 
Mobile phase: Toluene: Ethyl acetate: Acetic acid (55: 45: 1) 
Spray Reagent: Anisaldehyde sulphuric acid 
Sample concentration: 10 mg / 1.0 mL of HPLC grade Methanol 
Adsorbent: Silica gel 60 F254 (Merck pre-coated Al. Sheets - 1.05554) 
Solvent front run: Up to 9 cm  
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VI. 4.2. TLC and HPTLC fingerprint profile of flavonoids in L. aspera leaves  
 The TLC and HPTLC profile of flavonoid compounds of various solvent 
extracts of L. aspera are presented in figure 18 and 19. The Rf value and peak values 
are summarized and presented in table 15 and 16.  
Figure 18: TLC images of flavonoids profiling of L. aspera leaves 
 
Lane 01: Rutin (standard) 
Lane 02: Petroleum ether extract of L. aspera leaves 
Lane 03: Chloroform extract of L. aspera leaves 
Lane 04: Ethyl acetate extract of L. aspera leaves 
Lane 05: Isopropyl alcohol extract of L. aspera leaves  
Lane 06: Ethanol extract of L. aspera leaves 
Mobile phase: Ethyl acetate (100): Acetic acid (11): Formic acid(11) : Water(10) 
Spray reagent: 1% Aluminium chloride solution 
Figure 19: HPTLC fingerprinting profiles of flavonoids in L. aspera leaves 
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Figure 19: HPTLC fingerprinting profiles of flavonoids in L. aspera leaves 
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The HPTLC fingerprint study confirmed the presence of flavonoids 
compounds in the extracts of L. aspera leaves. Three flavonoid compounds found in 
ethanol extracts, 2 each in petroleum ether and isopropyl alcohol extracts and 1 each 
in chloroform and ethylacetate extracts of L. aspera leaves. HPTLC profile of L. 
aspera leaf is presented in Table 15 and 16. 
Table 15: Peak table with Rf values, height and area of flavonoids and unknown         
compounds present in L. aspera leaf extracts 
Track Peak Rf Height Area 
Assigned 
substance 
Rutin 1 0.67 609.5 21679.7 Rutin 
Rutin 2 0.77 31.1 598.4 Unknown 
PELA 1 0.66 17.1 329.1 Flavonoid 
PELA 2 - - - Unknown 
EALA 1 - - - Unknown 
CFLA 1 - - - Unknown 
IALA 1 - - - Unknown 
IALA 2 0.70 33.0 983.9 Flavonoid 1 
IALA 3 0.76 36.7 871.6 Flavonoid 2 
EELA 1 0.61 46.2 1575.8 Flavonoid 1 
EELA 2 0.66 63.7 1802.6 Flavonoid 2 
EELA 3 0.67 165.7 5368 Flavonoid 3 
PELA-petroleum ether extract of L. aspera; EALA-ethyl acetate extract of L. aspera; 
CFLA-chloroform extract of L. aspera; IALA-isopropyl alcohol extract of L. aspera; 
EELA-ethanol extract of L. aspera.  
 
Table 16: Summary of HPTLC fingerprint profile of flavonoids present in         
L. aspera leaves 
Rf value Rutin 
Petroleum 
ether 
Ethyl 
acetate 
Chloroform 
Isopropyl 
alcohol 
Ethanol 
0.61 - - - - - + 
0.65 - - + - - - 
0.66 - - - + - + 
0.67 + + - - - - 
0.70 - - - - + - 
0.74 - - - - - + 
0.76 - - - - + - 
0.78 + + - - - - 
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VI. 4.3. TLC and HPTLC fingerprint profile of steroids in L. aspera leaves  
The TLC and HPTLC profile of flavonoid compounds of various solvent 
extracts of L. aspera are presented in figure 20 and 21. The Rf value and peak values 
are summarized and presented in table 17.  
Figure 20: TLC images of steroids profiling of L. aspera leaves 
 
Lane 01: Stigmasterol (standard) 
Lane 02: Petroleum ether extract of L. aspera leaves 
Lane 03: Chloroform extract of L. aspera leaves 
Lane 04: Ethyl acetate extract of L. aspera leaves 
Lane 05: Isopropyl alcohol extract of L. aspera leaves  
Lane 06: Ethanol extract of L. aspera leaves 
Mobile phase: Toluene (55): Ethyl acetate (45) Acetic acid (1) 
Spray reagent: Spray reagent Anisaldehyde sulphuric acid reagent 
Figure 21: HPTLC fingerprinting profiles of steroids in L. aspera leaves 
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Figure 21: HPTLC fingerprinting profiles of steroids in L. aspera leaves 
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Table 17: HPTLC profile and Rf values of steroids present in different solvent 
extracts of L. aspera leaves 
Rf value Stigmasterol 
Petroleum 
ether 
Ethyl 
acetate 
Chloroform 
Isopropyl 
alcohol 
Ethanol 
0.20 - + - - - - 
0.21 - - - + - - 
0.23 - - + - - + 
0.23 - - - - + - 
0.27 - - - - - - 
0.30 - - - - + - 
0.35 - - - - - - 
0.39 - - - - - - 
0.40 - - + + + + 
0.52 - + - - - - 
0.58 - -  + - - 
0.60 - - + - - - 
0.62 + + - - + + 
0.63 - + + + + - 
0.66 - - - - - + 
0.71 - - - - - + 
0.72 - + - + - - 
0.77 + + - - + - 
0.80 - + - + - - 
0.81 - - - - - + 
0.83 - - - - - - 
0.89 - - + - - - 
0.91 - +   + + 
0.94 - - + - - - 
 
Above table shows the number of steroid compounds peaked at different Rf values in 
various solvent extracts of L. aspera leaves. The distribution of compounds (Rf) are 
varies from solvent to solvent, which indicate the number different type of steroidal 
compounds are present in each solvent.  The extracts of L. aspera leaf showed 
presence of stigmasterol related steroids as well as other steroidal compounds.   
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VI. 5. In vitro anti-diabetic studies 
VI. 5.1. MTT assay 
 MTT {3-(4, 5–dimethyl thiazol–2–yl)–5–diphenyl tetrazolium bromide} 
cytotoxic capacity was carried out on EELA and PELA.  The EELA exhibited 9.51%, 
19.44%, 36.45%, 57.07% and 63.89% of cytotoxic at 62.5, 125, 250, 500 and 1000 
µg/mL concentrations respectively. Whereas PELA exhibited 34.6%, 54.63.44%, 
80.22%, 85.27% and 90.49% at same concentrations respectively. Non-polar solvent 
extract (PELA) had shown better cytotoxic activity compared to polar solvent extract 
(EELA) against C2C12 cell line culture from rat skeletal muscles. The CTC50 values 
of PELA and EELA was found to be 110.75±5.55 µg/mL and 415.25±8.0 µg/mL 
respectively.  The complete details of cytotoxic activity is presented in table 19 and 
figure 22. 
Table 18:  Cytotoxic activity of polar and non-polar solvent extracts L. aspera leaves 
against C2C12 cell line 
Sl. 
No. 
Name of test sample 
Test Conc. 
(µg/mL) 
Cytotoxicity* 
(%) 
CTC50 (µg/mL) 
1 
EELA 
 
1000 
500 
250 
125 
62.5 
63.89±0.9 
57.07±1.9 
36.45±1.9 
19.44±1.3 
9.51±1.1 
 
415.25±8.0 
 
2 
PELA 
 
1000 
500 
250 
125 
62.5 
90.49±1.3 
85.27±0.9 
80.22±0.5 
54.63±2.0 
34.60±1.2 
 
110.75±5.5 
 
*Values are obtained from average of 3 determinants. 
PELA-petroleum ether extract of L. aspera; EELA-ethanol extract of L. aspera.   
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Figure 22: Cytotoxic activity of polar and non-polar solvent extracts L. aspera 
leaves against C2C12 cell line 
 
 
 
VI. 5.2. In vitro glucose uptake assay 
 Glucose uptake activity of PELA and EELA was determined in differentiated 
C2C12 cells. The percentage of glucose uptake activity was tested against 
rosiglitazone standard. The glucose uptake capacity of PELA was 17.2% and 48.19% 
at 250 µg/mL and 500 µg/mL concentrations respectively. Whereas EELA exhibited 
13% and 34.29% at the same concentrations. Thus, PELA (non-polar) showed better 
glucose uptake activity than EELA (polar).  The activity was tested twice with an 
average value 3 determinates. The complete details of in vitro glucose uptake assay 
are given in table 20 and figure 23. 
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Table 19: In vitro glucose uptake capacity of polar and non-polar solvent extracts 
L. aspera leaves against C2C12 cell line 
Sl. 
No. 
Name of the Test 
substances 
Test 
Conc. 
(mcg/mL) 
Glucose uptake percentage (mean±SD) 
T1* T2* Average 
1 
Standard 
(Rosiglitazone) 
100 124.43±6.71 125.38±2.57 124.90±4.64 
2 EELA 
500 34.65±2.09 33.93±5.60 34.29±3.84 
250 12.40±3.03 13.59±3.57 12.99±3.30 
3 PELA 
500 48.49±5.33 47.89±4.29 48.19±4.81 
250 17.75±2.00 16.65±5.27 17.2±3.63 
T1 - test 1, T2 - test 2, SD-standard deviation.  
*T1 and T2 values are obtained from average of 3 determinants. 
 
Figure 23: Glucose uptake capacity of polar and non-polar solvent extracts            
L. aspera leaves against C2C12 cell line  
 
Normal - Distilled water; Std - Rosiglitazone 
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VI. 6. Animal experimental studies 
VI. 6.1. Acute oral toxicity study 
 Acute oral toxicity study was performed according to the OECD-423 
guidelines. No significant toxic signs and behaviour was noted in any group during 14 
days observational time. Based on the acute oral toxicity study results, the dose of      
L. aspera extracts were fixed at 250 mg/kg (low dose) and 500 mg/kg (high dose) for 
anti-diabetic and anti-hyperlipidemic activity.  
Table 20: Grouping of animals in acute toxicity study (OECD 423 guidelines) 
Group Animals (N) Dose (mg/kg) 
1 3 5 
2 3 50 
3 3 300 
4 3 1000 
5 3 2000 
 
VI. 6.2 Effect of polar and non-polar solvent extracts of L. aspera leaves on    
serum glucose and insulin levels in rats with type 2 DM 
 Anti-diabetic effect of polar and non-polar solvent extracts of L. aspera leaves 
were investigated with low dose (250 mg/kg) and high dose (500 mg/kg) after acute 
toxicity studies. Reference drug glibenclamide (0.5 mg/kg) was found to have potent 
hypoglycemic effect and it reduced the serum glucose level by 87% on type-2 diabetic 
rats. Both EELA and PELA at 500 mg/kg significantly reduced the serum glucose 
levels in type-2 diabetic rats. PELA (non-polar) decreased the glucose level by 73% 
and EELA (polar) reduced the glucose level by 61% in treated animals. The insulin 
levels were moderately increased EELA and PELA treated animals. Body weights of 
the animals were also recorded during the study period. However, there was a mild 
weight gain in the treatment group which was not statistically significant compared to 
control group.  
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Figure 24: Trend of blood glucose levels (mg/dL) at initial, after induction and   
after treatment.  
 
 
Table 21: Effect of EELA and PELA on Blood glucose levels (mg/dL) at 0th, 2nd   
and 4th week of the treatment.  
Group 
# 
Group Name 
0th week of 
treatment 
(Week 4) 
2nd week of 
treatment 
(Week 6) 
4th week of 
treatment 
(Week 8) 
I Normal 95.66 ± 2.33 96.83 ± 3.43 99.50 ± 1.76 
II Diabetic 
control 
300.00 ± 86.02* 330.00 ± 81.73*§ 327.16 ± 36.66 * 
III Glibenclamide  
(0.5 mg/kg) 
338.33 ± 57.41* 176.00 ± 11.93*§ 108.33 ± 7.08 § 
IV EELA  
(250 mg/kg) 
343.33 ± 83.34* 203.83 ± 8.90*§ 
177.16 ± 11.14 
*§ 
V EELA 
(500 mg/kg) 
357.66 ± 61.58* 188.66 ± 10.34*§ 121.33 ± 14.23 § 
VI PELA 
(250 mg/kg) 
316.66 ± 74.47* 190.50 ± 14.11*§ 
138.33 ± 26.92 
*§ 
VII PELA  
(500 mg/kg) 
340.00 ± 166.25* 171.50 ± 16.26*§ 107.50 ± 10.19 § 
Statistical comparison: Values are presented as mean±SD (n=6); One-Way ANOVA 
followed by Dunnet’s test was performed. Group I compared with Group II, III, IV, 
V, VI and VII. *p value < 0.001; Group II compared with Group III, IV, V, VI and 
VII. § p value < 0.001. 
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Figure 25: Effect of EELA and PELA on blood glucose levels in rats with type 2 
DM at the end of 4 weeks treatment (week 8)  
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
 
Table 22: Effect of EELA and PELA on Insulin levels at the end of 4 weeks 
treatment (week 8)  
Group # Group Name Insulin levels (μIU/mL) 
I Normal 33.66 ± 2.74 
II Diabetic control 19.66 ± 0.50 * 
III Glibenclamide (0.5 mg/kg) 30.66 ± 2.08 § 
IV EELA (250 mg/kg) 22.17 ± 1.52 *  
V EELA (500 mg/kg) 26.33 ± 1.42 § 
VI PELA (250 mg/kg) 20.33 ± 2.90 *  
VII PELA (500 mg/kg) 28.50 ± 2.41 § 
Statistical comparison: Values are presented as mean±SD (n=6); One-Way ANOVA 
followed by Dunnet’s test was performed. Group I compared with Group II, III, IV, 
V, VI and VII. *p value < 0.001; Group II compared with Group III, IV, V, VI and 
VII. § p value < 0.001. 
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VI. 6.3. Effect of polar and non-polar solvent extracts of L. aspera leaves on total 
cholesterol and triglycerides level in rats with type 2 DM 
 The effect of polar and non-polar solvent extracts of L. aspera on serum 
triglycerides and total cholesterol in type-2 DM and hyperlipidemia induced rats were 
studied. Atorvastatin (10 mg/kg) was used as standard treatment. Results showed an 
increase in serum triglycerides and total cholesterol levels in diabetic rats. 
Administration of L. aspera extracts (250, 500 mg/kg) significantly decreased the 
serum triglycerides and total cholesterol when compared to normal and diabetic 
controls. EELA (polar) at dose of 250 and 500 mg/kg was found to have more 
effective than PELA (non-polar) at the same dose. EELA at 500 mg/kg showed 52% 
reduction in triglycerides and 58% in total cholesterol levels compared to PELA (41% 
and 56% respectively). 
Figure 26: Trend of blood total cholesterol levels (mg/dL) at initial, after    
induction and after treatment.   
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Table 23: Effect of EELA and PELA on total cholesterol levels at the end of 4 
weeks treatment (week 8)  
Group # Group Name Total cholesterol (mg/dL) 
I Normal 48..53 ± 5.73 
II Diabetic control 104.00 ± 3.08 a**** 
III Atorvastatin (10 mg/kg) 38.70 ± 1.83 b**** 
IV EELA (250 mg/kg) 40.77 ± 2.12 b**** 
V EELA (500 mg/kg) 35.57 ± 4.97 b**** 
VI PELA (250 mg/kg) 52.70 ± 4.80 b**** 
VII PELA (500 mg/kg) 41.37 ± 3.61 b**** 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
 
 
 Figure 27: Effect of EELA and PELA on total cholesterol levels in rats with type 
2 DM at the end of 4 weeks treatment (week 8)  
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 28: Trend of blood triglycerides level (mg/dL) at initial, after induction    
and after treatment.   
 
 
Table 24: Effect of EELA and PELA on triglycerides level at the end of 4 weeks 
treatment (week 8)  
Group # Group Name Triglyceride levels (mg/dL) 
I Normal 71.87 ± 7.18 
II Diabetic control 122.01 ± 2.28 a** 
III Atorvastatin (10 mg/kg) 72.80 ± 12.1 b** 
IV EELA (250 mg/kg) 74.97 ± 15.11 b** 
V EELA (500 mg/kg) 51.63 ± 19.11 b*** 
VI PELA (250 mg/kg) 84.23 ± 13.38 b* 
VII PELA (500 mg/kg) 61.50 ± 23.54 b** 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 29: Effect of EELA and PELA on triglycerides level in rats with type 2 
DM at the end of 4 weeks treatment (week 8)  
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
 
VI. 6.4. Effect of polar and non-polar solvent extracts of L. aspera leaves on       
HDL, LDL and VLDL levels in rats with type 2 DM 
 High density lipoproteins (HDL) were decreased in diabetic and 
hyperlipidemia induced rats. Low density lipoproteins (LDL) and very low-density 
lipoproteins (VLDL) were found to be increased in diabetic and hyperlipidemia 
induced rats.  Administration of L. aspera extracts reversed the levels in treated 
groups. PELA (non-polar) and the dose of 500 mg/kg significantly increased the HDL 
levels (p<0.001). Whereas both the EELA (polar) and PELA (non-polar) extracts 
significantly (p<0.001) decreased the LDL and VLDL in treated groups.   
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Figure 30: Trend of HDL-cholesterol levels (mg/dL) at initial, after induction    
and after treatment.   
 
 
 
Table 25: Effect of EELA and PELA on HDL-cholesterol levels at the end of 4 
weeks treatment (week 8)  
Group # Group Name HDL cholesterol (mg/dL) 
I Normal 36.77 ± 3.80 
II Diabetic control 19.33 ± 1.62 a** 
III Atorvastatin (10 mg/kg) 34.02 ± 3.65 b* 
IV EELA (250 mg/kg) 35.33 ± 2.57 b** 
V EELA (500 mg/kg) 41.97 ± 1.65 b*** 
VI PELA (250 mg/kg) 36.03 ± 9.25 b** 
VII PELA (500 mg/kg) 37.93 ± 7.43 b** 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 31: Effect of EELA and PELA on HDL-cholesterol levels in rats with type 
2 DM at the end of 4 weeks treatment (week 8)  
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
 
Figure 32: Trend of LDL-cholesterol levels (mg/dL) at initial, after induction        
and after treatment.   
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Table 26: Effect of EELA and PELA on LDL-cholesterol levels at the end of 4 
weeks treatment (week 8)  
Group # Group Name LDL cholesterol (mg/dL) 
I Normal 28.27 ± 5.76 
II Diabetic control 50.97 ± 8.42 a*** 
III Atorvastatin (10 mg/kg) 15.9 ± 2.85 b**** 
IV EELA (250 mg/kg) 20.53 ± 3.88 b**** 
V EELA (500 mg/kg) 15.97 ± 3.52  b**** 
VI PELA (250 mg/kg) 24.00 ± 2.75 b**** 
VII PELA (500 mg/kg) 20.97 ± 2.28 b**** 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
 
 
Figure 33: Effect of EELA and PELA on LDL-cholesterol levels in rats with type 
2 DM at the end of 4 weeks treatment (week 8)  
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 34: Trend of VLDL-cholesterol levels (mg/dL) at initial, after induction        
and after treatment   
 
 
 
Table 27: Effect of EELA and PELA on VLDL-cholesterol level at the end of 4 
weeks treatment (week 8)  
Group # Group Name VLDL cholesterol (mg/dL) 
I Normal 14.13 ± 4.16 
II Diabetic control 37.37 ± 2.28 a**** 
III Atorvastatin (10 mg/kg) 13.10 ± 2.11 b**** 
IV EELA (250 mg/kg) 16.87 ± 3.15 b**** 
V EELA (500 mg/kg) 14.87 ± 4.85 b**** 
VI PELA (250 mg/kg) 19.37 ± 1.13 b**** 
VII PELA (500 mg/kg) 17.11 ± 1.97 b**** 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 35: Effect of EELA and PELA on VLDL-cholesterol levels in rats with 
type 2 DM at the end of 4 weeks treatment (week 8)  
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
 
Table 28: Effect of EELA and PELA on TC-HDL ratio at the end of 4 weeks 
treatment (week 8)  
Group # Group Name TC-HDL ratio 
I Normal 1.328 ± 0.18  
II Diabetic control 5.396 ± 0.30 a**** 
III Atorvastatin (10 mg/kg) 1.150 ± 0.16 b**** 
IV EELA (250 mg/kg) 1.166 ± 0.13 b**** 
V EELA (500 mg/kg) 0.800 ± 0.12 b**** 
VI PELA (250 mg/kg) 1.527 ± 0.40 b**** 
VII PELA (500 mg/kg) 1.126 ± 0.27 b**** 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 36: Effect of EELA and PELA on TC-HDL ratio at the end of 4 weeks 
treatment (week 8) 
 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
 
VI. 6.5. Effect of polar and non-polar solvent extracts of L. aspera leaves on 
serum aspartate amino transferase (AST/SGOT) and alanine amino 
transferase (ALT/SGPT) levels in rats with type 2 DM 
 The effect of L. aspera leaf extracts on AST levels and ALT levels are 
depicted in figure 37 and 38. Both the serum AST and ALT levels were increased in 
diabetic rats. Administration of L. aspera extracts (PELA and EELA) decreased the 
AST levels by 15% and 12% respectively compared to control group; whereas both 
the EELA and PELA had significantly reduced (p<0.01) the ALT levels by 52% and 
42% respectively in diabetic and hyperlipidemic rats.  These results show the 
hepatoprotective effect of L. aspera leaves in rats with type 2 DM.  
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Figure 37: Effect of EELA and PELA on SGOT (AST) levels in rats with type 2 
DM at the end of 4 weeks treatment (week 8)  
 
 
Figure 38: Effect of EELA and PELA on SGPT (ALT) levels in rats with type 2 
DM at the end of 4 weeks treatment (week 8) 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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VI. 6.6. Effect of polar and non-polar solvent extracts of L. aspera leaves on 
serum creatinine, urea and uric acid levels in rats with type 2 DM 
 Serum urea, uric acid and creatinine levels were found to be increased in 
diabetic rats when compared to normal rats. Administration of L. aspera extracts at 
250 and 500 mg/kg dose significantly decreased the urea, uric acid and creatinine 
compared to diabetic control rats. At the dose of 500 mg/kg, EELA (polar) 
significantly decreased the serum urea levels and PELA (non-polar) significantly 
reduced the serum creatinine levels compared to glibenclamide and atorvastatin 
treated group. However, there was no significant between L. aspera extracts and 
standard drugs on uric acid levels. 
 
 
Figure 39: Effect of EELA and PELA on serum creatinine levels in rats with type 
2 DM at the end of 4 weeks treatment (week 8) 
 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 40: Effect of EELA and PELA on blood urea levels in rats with type 2 DM 
at the end of 4 weeks treatment (week 8) 
 
 
 
Figure 41: Effect of EELA and PELA on plasma uric acid levels in rats with type           
2 DM at the end of 4 weeks treatment (week 8) 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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VI. 6.7. Effect of polar and non-polar solvent extracts of L. aspera leaves on   
depression associated with induced type 2 DM and hyperlipidemia 
 Decreased in tail immersion time and increased immobility were observed in 
diabetic control animals. Treatment with PELA and EELA increased the mobility time 
in forced-swim model and decreased the tail immersion time in tail suspension model. 
This action indicates that L. aspera leaves can reduce the depression associated with 
diabetes and hyperlipidemia.  
Table 29: Effect of EELA and PELA on depression associated with type 2 DM 
(tail suspension test)   
Group # Group Name Before Treatment After Treatment 
I Normal 170.50±16.29 132.50±24.75 
II Diabetic control 179.83±27.77  87.83±18.16 a* 
III Standard 179.83±27.77 105.66±10.45 
IV EELA (250 mg/kg) 54.83±14.71 b** 114.00±14.25 
V EELA (500 mg/kg) 85.66±7.61 b* 128.00±20.33 
VI PELA (250 mg/kg) 116.00±21.45 128.66±19.38 
VII PELA (500 mg/kg) 78.16±12.58 b** 115.33±14.44 
 
Table 30: Effect of EELA and PELA on depression associated with type 2 DM 
(despair swim test)   
Group # Group Name Before Treatment After Treatment 
I Normal 122.33±4.77 141.00±6.79 
II Diabetic control 105.33±6.65 97.16±9.32 
III Standard 88.83±16.18 88.50±24.70 
IV EELA (250 mg/kg) 132.00±13.56 50.16±11.65 
V EELA (500 mg/kg) 94.00±16.06 71.83±11.18 
VI PELA (250 mg/kg) 99.50±10.32 73.33±8.75 
VII PELA (500 mg/kg) 124.83±18.30 124.33±16.34 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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VI. 7. In vivo antioxidant studies 
 In vivo antioxidant studies were performed in liver and kidney homogenates. 
Superoxide dismutase (SOD), lipid peroxide (LPO), glutathione peroxidase (GPx), 
reduced glutathione (GSH) and catalase (CAT) enzymatic activity were measured at 
end of the study. All these enzymes levels were decreased in rats with type 2 DM and 
hyperlipidemia. Treatment with PELA and EELA significantly increased the levels at 
the dose of 250 mg/kg (p<0.05) and 500 mg/kg (p<0.01).  
 
Table 31: Effect of EELA and PELA on SOD and CAT in kidney and liver of      
Type-2 DM and hyperlipidemia induced-rats at the end of 4 weeks 
treatment (week 8) 
 
Group 
Name 
SOD  
(Units of activity/mg proteins) 
CAT  
(units of activity/mg proteins) 
Kidney Liver Kidney Liver 
Normal 4.000±0.125 8.047±0.727 2.333±0.102 6.460±0.381 
T2DM 
2.407±0.231 
a*** 
5.437±0.196 
a** 
0.993±0.200 
a**** 
3.780±0.105 
a**** 
Standard 
2.593±0.571 
 
6.993±0.299 
1.860±0.222 
b*** 
5.120±0.240 
b* 
EELA250 
3.133±0.300 
 
5.860±1.077 
 
1.403±0.229 
b* 
4.300±0.432 
 
EELA500 
3.173±0.075 
 
7.447±0.800 
b* 
1.900±0.192 
b**** 
4.887±0.700 
 
PELA250 2.407±0.394 6.287±0.378 1.160±0.060 
5.373±0.523 
b** 
PELA500 
3.033±0.634 
 
7.153±1.203 
1.440±0.120 
b* 
5.573±0.567 
b** 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 42: Effect of EELA and PELA on SOD levels (kidney and liver) in rats 
with type 2 DM at the end of 4 weeks treatment (week 8) 
 
 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 43: Effect of EELA and PELA on CAT levels (kidney and liver) in rats    
with type 2 DM at the end of 4 weeks treatment (week 8) 
 
 
 
 Statistical comparison: Values are presented as mean±SD (n=6). One way 
ANOVA, followed by Dunnett comparison was performed. a - Group I (Normal) was 
compared with Group II (Diabetic control). b - Group II was compared with treated 
groups III, IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Table 32: Effect of EELA and PELA on LPO and GSH in kidney and liver of       
Type-2 DM and hyperlipidemia induced-rats at the end of 4 weeks 
treatment (week 8) 
Group 
Name 
LPO 
(nM of MDA/mg of protein) 
GSH 
(mM of GSH/mg protein) 
Kidney Liver Kidney Liver 
Normal 0.2133±0.012 0.7007±0.120 1.167±0.050 4.093±0.170 
T2DM 
0.1107±0.014 
a**** 
0.4260±0.018 
a**** 
0.8333±0.141 
a** 
2.873±0.271 
a** 
Standard 
0.2007±0.020 
b**** 
0.6707±0.066 
b*** 
1.160±0.052 
b** 
4.553±0.268 
b*** 
EELA250 
mg/kg 
0.1893±0.007 
b**** 
0.4367±0.066 0.9667±0.150 
4.333±0.500 
b** 
EELA500 
mg/kg 
0.1973±0.0132 
b**** 
0.5707±0.056 
b* 
1.213±0.130 
b** 
5.327±0.635 
b**** 
PELA250 
mg/kg 
0.1873±0.005 
b**** 0.5240±0.056 
1.060±0.040 
 
4.913±0.408 
PELA500 
mg/kg 
0.2253±0.016 
b**** 
0.6567±0.0535 
b*** 
1.333±0.102 
b** 
4.980±0.170 
b*** 
 
 
Figure 44: Effect of EELA and PELA on LPO levels (kidney and liver) in rats    
with type 2 DM at the end of 4 weeks treatment (week 8) 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 45: Effect of EELA and PELA on GSH levels (kidney and liver) in rats    
with type 2 DM at the end of 4 weeks treatment (week 8) 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Table 33: Effect of EELA and PELA on GPx in kidney and liver of Type-2 DM 
and hyperlipidemia induced-rats at the end of 4 weeks treatment    
(week 8) 
 
Group Name 
GPx (μmoles of oxidized GSH/min/mg protein) 
Kidney Liver 
Normal 1.737±0.080 1.373±0.061 
Diabetic control 1.133±0.250 a** 0.9233±0.040 a*** 
Standard 1.860±0.222 b*** 0.820±0.087 
EELA250 mg/kg 1.160±0.06 0.770±0.079 
EELA500 mg/kg 1.900±0.192 b*** 0.9933±0.112 
b* 
PELA250 mg/kg 0.9933±0.200 0.740±0.020  
PELA500 mg/kg 1.440±0.120 0.9167±0.051 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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Figure 46: Effect of EELA and PELA on GPx levels (kidney and liver) in rats    
with type 2 DM at the end of 4 weeks treatment (week 8) 
 
 
 
Statistical comparison: Values are presented as mean±SD (n=6). One way ANOVA, 
followed by Dunnett comparison was performed. a - Group I (Normal) was compared 
with Group II (Diabetic control). b - Group II was compared with treated groups III, 
IV, V, VI and VII.  (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05). 
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VI. 8. Histopathological studies          
 Microscopic studies of pancreas showed normal pancreatic acini and there was 
no evidence of destruction / cytoplasmic vacuolation / lymphocytic infiltrations 
(normal control group), with focal cytoplasmic vacuolation (disease control group) 
and few showed small in size and some showing lymphocytic infiltrates and focal 
destructions (standard treatment group).  PELA and EELA treated group did now 
show any evidence of destruction / cytoplasmic vacuolation / lymphocytic 
infiltrations. The histopathology reports confirmed that the administration L. aspera 
leaf extracts (EELA and PELA) minimized the damage of pancreatic cells and 
improved its functions. Individual histopathological presentation of pancreas in 
normal, diabetic and treated animals are presented in figure 48 to 54.  
 
Figure 47: Histopathology report of pancreas in Normal rats at the end of the         
study (week 8) 
 
(A) 10x shows normal pancreas; (B) 10x shows normal pancreatic acini      
with islets; (C) 40x shows normal acini with islets; (D) 40x shows normal 
islets. 
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Figure 48:  Histopathology report of pancreas in type 2 DM induced-rats at the 
end of the study (week 8) 
 
 
(A) 10x shows normal pancreas with islets; (B) 10x shows pancreas islets 
normal in number; (C) 40x shows focal cytoplasmic vacuolation; (D) 40x 
shows islets are normal in number. 
 
 
 
Figure 49: Histopathology report of pancreas in type 2 DM induced-rats after 4 
weeks treatment with Glibencalmide and atorvastatin (week 8) 
 
 
(A) 10x shows normal pancreatic acini and islets some showing small in size; 
(B) 10x shows pancreas with islets and acini; (C) 40x shows focal destruction; 
(D) 40x shows focal lymphocytic infiltrates. 
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Figure 50:  Histopathology report of pancreas in type 2 DM induced-rats after 4 
weeks treatment with EELA 250 mg/kg (week 8) 
 
 
(A) 10x shows normal pancreas; (B) 10x shows normal pancreatic acini with 
islets; (C) 40x shows normal acini with islets; (D) 40x shows normal islets.  
 
 
Figure 51: Histopathology report of pancreas in type 2 DM induced-rats after 4 
weeks treatment with EELA 500 mg/kg (week 8) 
 
 
(A) 10x shows few islets showing small in size; (B) 10x shows pancreas with 
normal in number; (C) 40x shows few islets with small in size; (D) 40x shows 
small islets with cytoplasmic vacuolation. 
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Figure 52: Histopathology report of pancreas in type 2 DM induced-rats after 
4 weeks treatment with PELA 250 mg/kg (week 8) 
 
 
(A) 10x shows islets are reduced in number; (B) 10x shows islets are small in 
size; (C) 40x shows focal cytoplasmic vacuolation; (D) 40x shows islets 
reduced in number and size. 
 
 
Figure 53: Histopathology report of pancreas in type 2 DM induced-rats after 
4 weeks treatment with PELA 500 mg/kg (week 8) 
 
 
(A) 10x shows normal in number and size; (B) 10x shows normal in number 
and some showing small in size; (C) 40x shows normal islets with acini;      
(D) 40x some showing small in size. 
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VII. DISCUSSION (Inferences) 
 Diabetes Mellitus and Dyslipidemia, becoming a substantial burden to 
healthcare globally. Successful treatment is very important to prevent or at least delay 
the onset of long-term complications.
126-128
  We can treat many such chronic illnesses 
with herbal medicines or drugs. Herbal drugs are effective and has very minimal 
adverse effects when compared to the available synthetic drugs to treat such chronic 
diseases and disorders. Such herbal drugs are a nature’s boon when compared to the 
severe adverse effects of the allopathic medical practice for diabetes. Despite the fact 
that the search for a complete and permanent cure for the disease is being pursued 
uncompromisingly by eluding physicians and researchers. These herbal remedies are 
still remaining unfamiliar to the up to date technical advances, which fascinating the 
wonderful opportunity for folklore or traditional medicines. 
 The world health organization (WHO) suggested and supports for evaluation 
of medicinal plants which are effective against different diseases.
37
 WHO has listed 
about 21,000 plants, which are used for medicinal purposes across the world. Out of 
which 2500 species are from India, and 150 species are used commercially on a large 
scale.
129
 India is the largest producer of medicinal herbs and is called as botanical 
garden of the world. Many Indian herbal plants have been identified which is useful in 
successful management of DM and hyperlipidemia.  
Ninety-five percent of the diabetes population is type 1 DM and remaining 5% 
only falls in type 2 DM.  Several studies with different herbs were investigated for its 
phytoconstituents and effect on diabetes and hyperlipidemia.   
The plant L. aspera is a well-known herbal medicinal plant used in the Indian 
medicines for treating several diseases. The plant was evaluated for many 
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pharmacological activities which included larvicidal, pubicidal, antimalarial, anti-
inflammatory, antiulcer, anti-cataractogenic, anti-hyperglycemic, anti-arthritic and 
many more.  
 In this current study, we have investigated the crude extracts of the herb         
L. aspera leaf for its anti-diabetic, anti-hyperlipidemic and antioxidant activity using 
polar and non-polar solvents.  
VII. 1. Phytochemistry 
 Chemical tests are useful in targeted isolation of new or biologically useful 
constituent with potential activities. It is economic and very important for localization 
of the targeted compounds. This procedure enables recognition of known metabolites 
in extracts or at the earliest stages of separation.  
 The present study was carried out on five different solvent extracts with 
increase in polarity. Different solvents were used to find out whether there is any 
major different in the isolation of compounds due to solvents nature and polarity. The 
solvents included, petroleum ether, ethanol, ethylacetate, chloroform and isopropyl 
alcohol. The results have confirmed that  L. aspera leaf contains flavonoids, alkaloids, 
glycosides, carbohydrates, steroids, terpenoids, tannins and phenolic compounds 
(Table 8). Among the five extracts PELA (non-polar) contains most of the compounds 
includes flavonoids, alkaloids, carbohydrate, phenolic compounds, tannins, steroids 
and fixed oils. Whereas EELA (polar solvent) contains alkaloids, flavonoids, 
carbohydrates, glycosides, tannins, phenolic compounds and saponins. 
 Quantitative estimation revealed, higher levels of flavonoids, alkaloids, 
tannins and steroids were present in both the EELA (polar) and PELA (non-polar). But 
the number of flavonoids and concentration were predominantly found in EELA 
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(Table 9). These phytochemicals exhibited various pharmacological and biochemical 
activities when ingested in animals.  
Chromatographic studies (TLC and HPTLC finger print profile) were used for 
identification and isolation of active phytoconstituents. HPTLC general profiling 
revealed, L. aspera contains many phytoconstituents which were found in different 
peaks at different points (figures 8-17). Finger print profile of flavonoids showed 
more number of flavonoid compounds were present in the polar solvent extract and 
the number decreases with the decrease in polarity (figure 18 and 19). Whereas, 
steroids profiling showed the number of compounds are irrelevant to polarity and 
found widely if all the five extracts (figure 20 and 21).  This is in agreement with the 
existing literature published.
130
  
VII. 2. In vitro antioxidant studies 
 Constant generation of free radicals occurs in living system and it causes 
extensive damages to the cells, tissues and organs which may lead to various disease 
statuses, especially degenerative disorders and inflammatory diseases. Antioxidants 
offers resistance to cells and prevent the diseases through scavenging the free radical 
molecules, inhibiting lipid peroxidations and my many other mechanisms.
131
   
 In this current study, we have evaluated the antioxidant potential of crude 
extracts of L. aspera leaves using five different solvents under different in vitro 
models which included DPPH radical scavenging, total antioxidant activity, nitric 
oxide scavenging and ABTS++ reduction assay.  
The DPPH scavenging activity of the extracts were evaluated using ascorbic 
acid standard. Higher the antioxidant contents produced higher the DPPH reduction. 
PELA (non-polar) exhibited the maximum DPPH scavenging with the value of 92% at 
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a concentration of 100 μg/ml with IC50 value of 18.96 μg/ml and it showed the 
antioxidant activity in a concentration dependent manner (20 to 92 %) in the DPPH 
assay. The scavenging activity of leaves of L. aspera extracts are in the order of 
petroleum ether > ethanol > isopropyl alcohol > ethyl acetate > chloroform.  
 Total antioxidant capacity of isopropyl alcohol extract was found to be higher 
(82% at 100 µg/mL) when compared to other solvents used. The total antioxidant 
capacities of different solvent extracts of leaves of L. aspera at various concentrations 
(10-100 μg/ml) were in the following order: isopropyl alcohol > petroleum ether > 
ethanol > ethyl acetate > chloroform.  
 Nitric oxide is a free radical produced from mammalian cells and it involved 
in various physiological processes. The excess production of nitric oxide is directly 
toxic to the cells and associated to septic shock, vascular collapse, diabetes mellitus 
and arthritis.
132
  Our study results showed, crude extracts of L. aspera leaves scavenge 
the free nitric oxides in the medium and prevent the formation of nitrite. PELA (non-
polar) exhibited higher nitric oxide scavenging at the concentration of 100 µg/mL and 
the order of nitric oxide scavenging activity of various solvent extracts of L. aspera 
was found to be petroleum ether > ethyl alcohol > chloroform > ethyl acetate > 
isopropyl alcohol. 
 ABTS assay is a decolourization method, the ABTS oxidant generated from 
2,2,-azinobis (3-ethylbenzoline-6-sulfonic acid) by persulfate oxidation. The 
antioxidant activity of extracts of leaves of L. aspera in this method is due to either 
inhibiting or scavenging the radicals. Because both the inhibition and scavenging 
activity were reported in earlier study.
133
 EELA produce the maximum activity 
compared to other extracts. The order of antioxidant potency of L. aspera leaf extract 
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in our study was found to be, ethanol > petroleum ether > chloroform > ethyl acetate 
> isopropyl alcohol. 
 Free radicals are capable of damaging cellular molecules, DNA, proteins and 
lipids can alter the functions at cellular level. Recent studies suggested that 
antioxidants which are capable of neutralizing free radicals can be effective in 
preventing experimentally induced-diabetes in animal models.
134,135
 and also it 
reduces the severity of diabetes related complications.
136
 
Overall, in vitro antioxidant studies suggested that L. aspera leaves are 
potential source of phytoconstituents which possesses very good antioxidant 
properties. This activity could be attributed to the phyto-ingredients such as 
flavonoids, alkaloids, phenolic compounds, terpenoids, tannins and steroids present in 
the L. aspera leaves.  
VII. 3. In vitro anti-diabetic studies 
 Skeletal muscle is the primary responsible site for postprandial glucose use 
and it is the most abundant tissue in the whole body.
137
 Defects in insulin stimulated 
skeletal muscle glucose uptake are common pathological states in type 2 diabetes.
101
 
In vitro anti-diabetic study was carried out on C2C12 cell lines. Based on 
preliminary phytochemical screening, quantitative estimation and chromatographic 
evaluations, PELA and EELA were selected for the in vitro antidiabetic activity.  
 The results of our current study clearly demonstrated the anti-diabetic potency 
of polar and non-polar solvent extracts obtained from L. aspera under in-vitro models. 
Among the two extracts used, PELA (non-polar) exhibited better cytotoxic activity in 
C2C12 cell line compared to EELA (polar). The CTC50 values of PELA and EELA 
were found to be 110.75±5.5 µg/mL and 415.25±8.0 µg/mL respectively (Table 18). 
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Whereas, PELA (non-polar) showed enhanced glucose uptake activity than EELA 
(polar) in C2C12 cell line at same concentrations (Figure 23).  
VII. 4. Pharmacology 
 The present study has been undertaken to evaluate the anti-diabetic, anti-
hyperlipidemic and antioxidant activities of polar (EELA) and non-polar (PELA) 
solvent extracts of L. aspera leaves on type-2 DM and hyperlipidemia induced-rats. 
The selection of extracts for the pharmacological activities were based on the results 
of preliminary phytochemical screening, quantitative estimation and chromatographic 
studies.  
Also, we evaluated the effect of EELA and PELA on biochemical parameters 
(SGOT, SGPT, blood urea, serum creatinine and plasma uric acid) and in vivo 
antioxidant enzymes (SOD, CAT, GPx, GSH and LPO in liver and kidney) in rats 
with type-2 DM. Addition to this we also looked the effect of EELLA and PELA on 
stress associated with diabetes using anti-depression rat models. Histopathological 
examination on pancreas was performed at the end of the study.  
VII. 4.1. Acute oral toxicity study 
 The present study indicates various doses 5 mg, 50 mg, 300 mg, and 2000 mg 
of EELA and PELA did not produce any signs of acute toxicity in normal mice. 
Hence, the extracts of L. aspera leaf can be used safely in the experimental studies. 
Based on the acute toxicity study results the doses were fixed at 250 mg/kg as low 
dose and 500 mg/kg as high dose for the anti-diabetic and anti-hyperlipidemic studies.  
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VII. 4.2. Anti-diabetic activity 
 Many number of herbal remedies are suggested for diabetes and diabetic 
related complications in the literatures.
138,139
 Only limited investigational studies are 
available on antihyperglycemic effect of L. aspera
83-85
 and these studies are very 
preliminary and basic using a single extract. We have used two different extracts 
(polar and non-polar) for the anti-diabetic activity in type 2 DM. Present study results 
are in agreement with earlier studies and indicated that both EELA and PELA 
significantly decreased the blood glucose levels in rats with type 2 DM. Both the 
EELA and PELA produced significant anti-diabetic effect (p<0.0001) on rats with 
type 2 DM. This effect was similar to that of standard drug glibenclamide. Anti-
diabetic effect of PELA (non-polar) was slightly better than EELA (polar), but not 
statistically significant.  
Insulin increases the hepatic glycolysis through increased activity of 
glucokinase, phosphofructokinase and pyruvate kinase.
140
 Insulin deficiency and 
associated glycogenolysis leads to decreased liver glycogen level.
141
 The possibility 
of restoring liver glycogen level in STZ-induced type 2 DM rats by the administration 
of EELA and PELA, could be attributed to the elevated secretion of insulin. 
In our present study insulin levels were significantly decreased (p<0.001) in 
diabetic rats and administration of EELA and PELA at the dose of 500 mg/kg 
significantly increased (p<0.001) the insulin levels towards normal control.  
VII. 4.3. Anti-hyperlipidemic activity 
 Diabetes is also associated with hyperlipidemia.
142 
The levels of serum 
triglycerides and total cholesterol were significantly decreased in diabetic rats after 
the administration of EELA and PELA. These effects may be attributed to lower 
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activity of cholesterol biosynthesis enzymes and/or reduced level of lipolysis, which 
are usually under the control of insulin. There are reports available on other medicinal 
plants have hypoglycemic and hypolipidemic effects that can prevent complications 
of lipid profiles in coexisting DM and hyperlipidemia.
143
  
In our present study, both the EELA and PELA significantly decreased the 
total cholesterol levels (p<0.0001) and serum triglycerides levels (p<0.001) in rats 
with type 2 DM. The HDL-cholesterol levels were significantly decreased (p<0.01) in 
type-2 diabetic rats and administration of EELA and PELA significantly increased the 
HDL-cholesterol levels (p<0.001 and p<0.01 respectively). This activity is slightly 
better in EELA (polar) compared to PELA (non-polar). Also, higher effect was seen in 
higher dose. These findings strengthen the hypolipidemic effect of L. aspera leaf.  
The LDL-cholesterol an VLDL-cholesterol levels were significantly increased 
in type-2 diabetic rats. Treatment with EELA and PELA significantly decreased the 
LDL and VLDL cholesterols levels (p<0.0001).  
VII. 4.4. Biochemical parameters 
Our study data showed that serum creatinine, urea and uric acid levels were 
increased in rats with type 2 DM. This increase may be due to metabolic disturbances 
occurs in diabetes condition which reflected in high activities of lipid peroxidation, 
increased level of total cholesterol and triglycerides and cholesterol levels.
144,145
 
Elevation of the serum urea and creatinine are the significant marker of renal 
dysfunction in diabetes. Besides, protein glycation in DM may leads to muscle 
wasting and increased release of purine, which is the main source of uric acid as well 
as in activity of xanthine oxidase.
145
 The present study results revealed that, 
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administration of EELA and PELA decreased the levels of creatinine (p<0.5), urea 
(p<0.05) and uric acids in blood.   
 An increased level of serum enzymes including SGOT (AST) and SGPT 
(ALT) are the indicative markers for the hepatic disorders in diabetes which reflect 
the active liver damage associated with diabetic conditions.
146,147
 Streptozotocin can 
alter the liver functions. Since the activity of SGOT and SGPT were significantly 
higher than those of normal values.  In our study, we observed an increased level of 
SGOT and SGPT in rats with type 2 DM. Treatment with PELA (non-polar: p<0.001) 
and EELA (polar: p<0.01) significantly decreased the SGPT levels and SGOT levels. 
These reduction in agreement with the earlier study reported by Prince et al.
148
 in 
STZ-induced diabetic rats and Sheweita et al.
149
 
VII. 4.5. Antioxidant enzymes 
 Decreased activity of SOD and CAT in the kidney and liver tissue have been 
observed in rats with type 2 DM, and this could be due to accumulation of super oxide 
and hydrogen peroxide radicals.
131,150
 Administration of EELA and PELA increased 
the activity of SOD and CAT, indicates that L. aspera leaf has free radical scavenging 
activity.  
Glutathione is an important intercellular peptide that exhibit multiple 
antioxidant effects.
151
 The observed, decreased level of GSH in type 2 DM is in 
consistent with the previous findings.
152
 It suggests that, hyperglycemia may lead to 
enhanced activity of polyol pathway to promote GSH depletion, which creates an 
imbalance of hepatocytes, nephrons, pancreatic cells in DM. Sustained oxidative 
insult in cellular membrane lead to accumulation of malondiadehyde (a stable end 
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product of lipid peroxidation). These changes implicates the development of long 
term complications associated with DM.
153
   
The results of our current study indicate polar and non-polar solvent extracts 
of L. aspera leaves were exhibited antioxidant effect by increasing SOD, CAT, GPx. 
GSH and LPO levels in vivo. 
VII. 4.6. Histopathological studies          
 Histopathological studies clearly indicated islets are normal in number and 
size in the normal rats.  Hamaguchi et al.
154
 showed the ultrastructure of the islet of 
pancreas can be affected by various glucose and oxygen concentration. We noted 
small in size and numbers with focal cytoplasmic vacuolation in type 2 DM rats. 
Whereas EELA and PELA treated groups showed, increased in number and size of 
normal cells at the end of 4 weeks treatment and now show cytoplasmic vacuolation 
or lymphocytic infiltrations. With the above findings it can be speculated, EELA        
(500 mg.kg) and PELA (500 mg/kg) produced the compensatory effect on pancreatic 
beta-cells in rats with type 2 DM and may induced the production of insulin secretion. 
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VIII. SUMMARY AND CONCLUSION 
Diabetes mellitus (DM) reached epidemic proportions worldwide and has a 
substantial burden on healthcare services. Prevalence of diabetes is increasing 
globally, particularly in developing countries. Traditionally DM was treated with 
herbal remedies (plants), diet and physical exercise.  
Hyperlipidemia is a diverse group of disorders usually associated with DM 
and presented as increased in triglycerides, total cholesterol, and lipoproteins in the 
bloodstream that leads to atherosclerosis.  
WHO warns that deaths due to diabetes will increase by 80% in some regions, 
over the period of next ten years. India host to the largest diabetes population in the 
world, with an estimate of approximately 62 million individuals and will increase 
further. ICMR reported, about 5 million peoples were affected from Tamil Nadu. 
Most of the recent studies projected about 300 million peoples get affected by 
diabetes by 2025.  
The cost of diabetes management is high, especially when associated with 
other complications. Herbal medicines are believed to be more effective with lesser 
side effects when compared to commercially available synthetic drugs.  
Medicinal plants are the basic source of modern medicine. The earliest 
recorded evidence of their use in Indian, Chinese, Egyptian, Greek, Roman and Syrian 
texts dates back to about 5000 years. Herbal medicine is still the mainstay of about 
75–80% of the world population, mainly in the developing countries, for primary 
health care because of better cultural acceptability, better compatibility with the 
human body and lesser side effects.  
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India is sitting on a gold mine of well-recorded and well-practiced knowledge 
of traditional herbal medicines. India is having over 45,000 plant species and one of 
the 12 mega biodiversity centres.  
Herbal medicines gained an extraordinary amount of popularity in the past 
several decades. High usage of herbal medicines is often in immigrants and patients 
with diseases such as difficult-to-treat which include advanced cancer and acquired 
immunodeficiency syndrome (AIDS). Approximately 30% of the general population 
use the herbal products. 
WHO suggested and supports for evaluation of medicinal plants which are 
effective against different diseases. Many Indian herbal plants have been identified 
which is useful in successful management of DM and hyperlipidemia. 
The plant L. aspera is a well-known herbal medicinal plant used in the Indian 
medicines for treating several diseases, which include larvicidal, pupicidal, 
antimalarial, anti-inflammatory, antiulcer, anti-cataractogenic, anti-hyperglycemic, 
antarthritic and many more.   
However, no study has ever compared the anti-diabetic, anti-hyperlipidemic 
and antioxidant activity of L. aspera leaves in type-2 DM with two different (polar 
and non-polar) solvent extracts.  
In this present, we have evaluated the anti-diabetic, anti-hyperlipidemic, in 
vitro and in vivo antioxidant activities of L. aspera leaf using polar (ethanol) and non-
polar (petroleum ether) solvent extracts.  
Preliminary phytochemical studies in L. aspera leaves confirmed the presence 
of flavonoids, alkaloids, tannins, steroids, phenolic compounds and steroids in both 
the polar (EELA) and non-polar (PELA) solvent extracts.  
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Quantitative estimation showed, a considerable amount of flavonoids, 
alkaloids and phenolic compounds in L. aspera leaf extracts. Chromatographic studies 
revealed, L. aspera leaf is a good source of flavonoids, steroids and many other 
phytoconstituents.  
In vitro antioxidant activity proved that, L. aspera leaf contains abundant 
phytoconstituents which possess antioxidant properties. The antioxidant activity is 
widespread in both the polar and non-polar solvent extracts of L. aspera.  
In vitro anti-diabetic activity confirmed that L. aspera leaf has better cytotoxic 
properties on C2C12 cell line. PELA (non-polar) exhibited better cytotoxic properties 
compared to EELA (polar), whereas, EELA (non-polar) showed enhanced glucose 
uptake activity than PELA (polar). 
Acute toxicity studies did not show any toxic signs in animals up to 2000 
mg/kg dose of EELA and PELA 
 The data of our present study results revealed that the polar and non-polar 
solvent extracts of L. aspera leaves significantly decreased the serum glucose level in 
rats with type 2 DM at the dose of 250 mg/kg and 500 mg/kg.  
The anti-diabetic effect was found to be significantly higher in non-polar 
solvent extract (PELA) compared to polar solvent extract (EELA). Increased activity 
was observed with higher doses.  
L. aspera leaf extracts possess remarkable anti-hyperlipidemic effect in rats 
with type 2 DM along with hepatoprotective activity. Both the polar and non-polar 
solvent extracts increased the HDL-cholesterol levels and decreased the total 
cholesterol levels and triglycerides levels.    
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The anti-hyperlipidemic activity was profound in polar solvent extract 
(EELA), compared to non-polar solvent extract (PELA). 
Antioxidant enzymes include SOD, CAT, GSH, GPx and LPO levels were 
decreased in rats with type 2 DM. An increased level of these antioxidant enzymes 
were observed after administration of L. aspera leaf extracts, which showed the 
antioxidant activity in vivo.  
Blood urea, creatinine and uric acid levels were increased in rats with type 2 
DM due to metabolic disturbances and these levels were reversed when L. aspera 
extract administered.  
SGPT (ALT) and SGOT (AST) levels were increased in rats with type 2 DM 
and a reduction was noted after the treatment with L. aspera leaf extracts.  
The anti-oxidant and free radical scavenging activity of EELA and PELA is 
one of the mechanism associated with anti-diabetic and anti-hyperlipidmic activity. 
The presence of phyto-ingredients such as flavonoids, phenolic compounds, 
alkaloids, terpenoids and tannins in polar and non-polar solvent extracts of L. aspera 
leaf is justified the anti-diabetic and anti-hyperlipidemic activity.  
From the above results, we may be concluded that, L. aspera leaves have 
promising anti-diabetic, anti-hyperlipidemic and antioxidant activity in rats with type-
2 diabetes. The results of this study warrant further research on isolation and 
characterization of active principle responsible for the anti-diabetic effect and anti-
hyperlipidemic effect in type-2 diabetes and hyperlipidemia before its clinical use. 
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IX. IMPACT OF THE STUDY 
  
 The current study highlighted a number of researchable aspects that could be 
pursued further by anti-diabetic, anti-hyperlipidemic and anti-oxidant research 
studies on L. aspera leaves. 
 The present study confirmed that many active phyto-ingredients are presented in 
the L. aspera leaves. Advanced level analytical study is recommended for 
isolation, identification and purification of different active principle present in 
different solvent extracts of L. aspera leaf. 
 Current study revealed L. aspera possesses anti-diabetic, anti-hyperlipidemiac and 
antioxidant activities. Further pharmacological studies and molecular level 
investigations are recommended to understand the clear mechanism of anti-
diabetic and anti-hyperlipidemic activity of L. aspera leaves. 
 We further recommended for pharmacokinetic studies and acute, sub-acute and 
chronic toxicological studies in animals before usage in humans.  
 Clinical evaluations and different levels of clinical research are recommended 
before the therapeutic use.  
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